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Summary
Tuberous sclerosis is an autosomal dominant multisystem disorder characterised by the 
development of benign tumours in many organs, including the brain, skin, kidneys and 
heart, seizures and intellectual disability.
The condition results from mutations in either of two genes, TSC1 (encoding TSC1) or 
TSC2 (encoding TSC2). Loss of functional TSC1 or TSC2 leads to activation of 
mTORCl (mammalian target of rapamycin complex 1), a key regulator of multiple 
cellular processes including cell growth and division.
Lymphangioleiomyomatosis (LAM) is a lung disorder which can lead to respiratory 
failure and is characterised by the proliferation of abnormal ‘LAM’ cells LAM occurs in 
patients with tuberous sclerosis and can also occur as a sporadic disorder due to
acquired mutations in TSC2. Renal angiomyolipomas are benign tumours which
affects80% of patients with tuberous sclerosis and 40% of patients with sporadic LAM.
Sirolimus is an inhibitor of mTORCl and is used in clinical practice as an
immunosuppressant. Preclinical studies suggest that TSC1 or TSC2 deficiency renders
cells sensitive to mTOR inhibition.
This thesis describes a phase 2 trial to assess the safety and efficacy of 2 years of 
treatment with sirolimus for renal angiomyolipomas in patients with tuberous sclerosis 
or LAM. Response of angiomyolipoma was the primary efficacy end point. Effects of 
sirolimus on lung function and neurocognitive function are also reported.
Our data show an angiomyolipoma response rate, by RECIST criteria, of 50% in the 
intention to treat population. There was little change in lung function. Recall but not 
recognition memory tended to improve. Adverse events were common and consistent 
with the known toxicities of sirolimus. Our findings suggest that mTOR inhibition is a 
potential therapeutic strategy in the treatment of tuberous sclerosis and 
lymphangioleiomyomatosis.
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Chapter 1: The clinical features of tuberous sclerosis and 
lymphangioleiomyomatosis
1.1 Tuberous sclerosis
Tuberous sclerosis (TSC) is an autosomal dominant, multisystem disorder affecting 
approximately 1 in 6,000 individuals [1]. The condition affects multiple organs and has 
a variable phenotype, both in terms of the type and severity of features seen in patients. 
The main features of the condition [2] are set out below:
1.1.1 Neurological
The most common, and often the most disabling features of tuberous sclerosis, are 
seizures, intellectual disability and neurobehavioral abnormalities, such as autistic 
spectrum disorder. The characteristic macroscopic brain lesions associated with 
tuberous sclerosis are cortical and subcortical tubers, subependymal nodules in the 
periventricular zone lining the lateral ventricles and subependymal giant cell 
astrocytomas. Tubers are developmental abnormalities of the cerebral cortex 
characterized histologically by a loss of the normal six-layered structure of the cortex 
and by dysmorphic neurons, large astrocytes, and a unique type of cell known as a giant 
cell [3]. Subependymal giant cell astrocytomas are tumours of mixed glial and neuronal 
lineage. Growth of these lesions can block circulation of the cerebrospinal fluid, leading 
to progressive ventricular dilatation and increased intracranial pressure. Subependymal 
nodules are asymptomatic hamartomas arising from the walls of the lateral and third 
ventricles.
White matter abnormalities seen by imaging in patients with tuberous sclerosis include 
superficial white matter abnormalities associated with cortical tubers, radial white
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matter bands and cyst like white matter lesions [4]. Superficial white matter 
abnormalities are related to almost all cortical tubers and reflect reduced myelin or 
increased gliotic reaction. Radial white matter bands reflect developmental migration 
defects of neurons and glial cells. White matter cyst like lesions are located in deep 
white matter and although the pathogenesis of cyst like lesions remains unclear, they are 
considered to reflect cystic degeneration of white matter or dilated perivascular spaces. 
Diffusion tensor imaging has shown that white matter structures that appear normal on 
conventional magnetic resonance imaging (MRI) may be accompanied by 
microstructural changes such as gliosis and myelinisation defects [5].
Around 80% of children with tuberous sclerosis have seizures [6] and the commonest 
presentation of the condition is with seizures, particularly infantile spasms, in infancy or 
early childhood [7]. Many types of seizure have been reported. The seizures are often 
refractory to treatment and may require the use of multiple antiepileptic drugs. Infantile 
spasms, which are associated with a poor cognitive prognosis, occur in 20-30% of 
children with tuberous sclerosis.
The distribution of intelligence quotient (IQ) scores of individuals with tuberous 
sclerosis suggests the existence of two distinct subgroups [6]. Approximately 30% are 
profoundly impaired with very low IQs (too low to be assessed by standardized 
measures of cognitive function); the remaining 70% have normally distributed IQs with 
a slight reduction in mean IQ relative to unaffected individuals. This second group is 
affected by specific cognitive deficits, such as deficiency in long term memory skills, 
attentional skills and executive skills [8-10].
Neurodevelopmental disorders, including attention deficit hyperactivity disorder, 
aggressive /disruptive behaviour and autistic spectrum disorder, are often seen in people
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with tuberous sclerosis. Approximately 20-60% of patients with tuberous sclerosis 
meet criteria for autistic spectrum disorder, with the criteria being met in 17% of those 
with an IQ in the normal range [8]. In adults, psychiatric features such as depression and 
anxiety are also frequently encountered [11].
1.1.2. Renal
Renal features of tuberous sclerosis include angiomyolipomas (AMLs), oncocytomas, 
simple cysts, polycystic kidney disease and renal cell carcinoma [12]. AMLs are found 
in approximately 80% of tuberous sclerosis patients. They are usually multiple and 
bilateral and often asymptomatic but AMLs can cause flank pain, impair renal 
function, and spontaneously bleed causing haematuria and occasionally life threatening 
haemorrhage [13]. A retrospective study of 102 patients with renal AMLs (both 
sporadic and tuberous sclerosis associated) with a median follow up of 4 years showed 
no evidence of spontaneous regression of any lesions [14].
Current conventional management options are observation or active intervention by 
either surgical resection or selective arterial embolisation. Some investigators have 
suggested that prophylactic renal selective arterial embolisation is the management of 
choice in all patients with symptomatic lesions or asymptomatic lesions of >4cm, as 
they may be at higher risk of rupture/haemorrhage. However, a recent study used digital 
subtraction angiography to classify AMLs into three grades (grade 1, minimal 
vascularity; grade 2, moderate vascularity; grade 3, marked vascularity) and found that 
none of the asymptomatic grade 1 tumours caused bleeding [15]. Hence, it might be that 
the extent of vascular tissue in an AML is the important predictor of subsequent 
haemorrhage, rather than the size of the overall tumour.
19
Renal cysts are common in tuberous sclerosis and usually asymptomatic but a 
polycystic kidney phenotype occurs in those patients with a contiguous deletion of 
TSC2 and PKD1 genes, who often progress to renal failure in early adult life [16]. The 
overall incidence of renal cell carcinomas in patients with tuberous sclerosis is thought to 
be similar to that in the general population but renal cell carcinomas associated with 
tuberous sclerosis tends to occur in younger patients [17]. A variety of types of renal cell 
carcinoma, including clear cell, papillary, and chromophobe carcinoma, have been reported 
in patients with tuberous sclerosis.
1.1.3 Pulmonary
Lymphangioleiomyomatosis (LAM) is a rare disorder of the lungs and lymphatics 
which can occur sporadically or in association with tuberous sclerosis [18]. LAM 
almost exclusively affects females and radiographic studies suggest it affects 40% of 
female patients with tuberous sclerosis, although many of these women are 
asymptomatic [19]. LAM is discussed further in section 1.2.
Focal proliferations of type II pneumocytes, termed multifocal micronodular 
pneumocyte hyperplasia (MMPH), may also be a pulmonary manifestation of tuberous 
sclerosis but is not thought to be clinically significant [20].
1.1.4 Skin
Several types of skin lesion can occur in tuberous sclerosis [2]. Hypomelanotic macules 
are often present at birth or develop during infancy and are best seen in ultraviolet light 
using a Wood’s lamp. Facial angiofibroma are flesh coloured or red papules, typically 
occurring over the nose, nasolabial folds, cheeks and chin, usually developing by the 
age of 5 years. Shagreen patches, which are elevated irregular brown or flesh coloured 
lesions, typically develop in the lumbar sacral area during childhood. Ungual fibromas
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are flesh-coloured or pink nodules that occur on the finger or toe nail beds. A linear 
depression in the nail can suggest the presence of a subungual fibroma. Gingival 
fibromas can also occur.
1.1.5 Cardiac
Cardiac rhabdomyomas are an early manifestation of tuberous sclerosis, appearing at 22 
to 28 weeks of gestation [21]. They usually regress during childhood and are normally 
asymptomatic but can be associated with obstructive heart failure or arrhythmias. 
Cardiac rhabdomyomas can be an unexpected finding on routine antenatal scans where 
they are associated with a substantial risk of tuberous sclerosis, especially if the lesions 
are multiple.
1.1.6 Ophthalmological
The commonest ophthalmologic manifestations of tuberous sclerosis are retinal 
hamartomas [22]. They seldom affect vision.
1.1.7 Neuroendocrine tumours
Case reports have documented the occurrence of neuroendocrine tumours of the 
pituitary, pancreas and parathyroid, as well as phaeochromocytomas in patients with 
tuberous sclerosis. It is unclear if this is just coincidental or there is an association 
between neuroendocrine tumours and tuberous sclerosis [23].
1.1.8 Gastrointestinal polyps
Gastrointestinal polyps (generally hamartomatous) may be common in patients with 
tuberous sclerosis [24-27]. The prevalence of gastrointestinal polyps is uncertain but 
may be underestimated because they are usually asymptomatic. Gould et al documented 
that 14 of 18 (78%) patients with tuberous sclerosis had intestinal polyps (25).
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1.1.9 Skeletal involvement
Bone manifestations of tuberous sclerosis include cyst like lesions, hyperostosis of the inner 
table of the skull, osteoblastic changes, periosteal new bone formation, and scoliosis [28].
1.1.10 Clinical assessment and diagnostic criteria
The diagnosis of tuberous sclerosis is usually based on clinical and radiological features 
using the criteria shown in table 1 [29]. These are divided into major and minor criteria. 
As many of the features associated with tuberous sclerosis can occur sporadically, the 
presence of one major feature suggests but does not establish the diagnosis. The minor 
features are even less specific. No single feature is diagnostic and many show age 
related penetrance.
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Table 1: Diagnostic criterion for tuberous sclerosis [29]
Major Features
• Facial angiofibromas or forehead plaque
• Nontraumatic ungual or periungual fibromas
• Hypomelanotic macules (three or more)
• Shagreen patch (connective tissue nevus)
• Multiple retinal nodular hamartomas
• Cortical tuber 1
• Subependymal nodule
• Subependymal giant cell astrocytoma
• Cardiac rhabdomyoma, single or multiple
• Lymphangiomyomatosis2
• Renal angiomyolipoma 2
Minor Features
• Multiple randomly distributed pits in dental enamel
• Hamartomatous rectal polyps
• Bone cysts
• Cerebral white matter radial migration lines 1
• Gingival fibromas
• Nonrenal hamartoma
• Retinal achromic patch
• "Confetti" skin lesions
• Multiple renal cysts
Definite tuberous sclerosis: Two major features or one major feature plus two 
minor features
Probable tuberous sclerosis: One major feature plus one minor feature 
Possible tuberous sclerosis: One major feature or two or more minor features
1. I f  the cerebral cortical dysplasia and cerebral white matter migration tracts occur 
together they should be counted as one rather than two features o f TSC.
2. When both lymphangioleiomyomatosis and renal angiomyolipomas are present, other 
features o f tuberous sclerosis must be present before a definite diagnosis is made.
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1.1.11 Clinical management and surveillance
Clinical management requires a multi-disciplinary approach tailored to the specific 
problems of the affected individual. Ideally, patients should be seen by specialists with 
an interest in the condition. For some areas there are disease specific deviations from 
standard practice, such as in anti-epileptic drug selection, and there is a risk of over 
treatment, for example, unnecessary kidney resection due to atypical AMLs being 
mistaken for renal carcinomas.
In individuals suspected of having tuberous sclerosis the following initial assessments 
should be considered to establish the diagnosis and to identify complications amenable 
to treatment [30]:
• Medical history and three generational family history
• Clinical examination, including fundoscopy and skin examination under
ultaviolet light
• Cranial imaging e.g. MRI
• Renal ultrasound
• Echocardiography in infants
• Electroencephalography, if seizures are present
• Neurodevelopmental and behavioural evaluation
• Chest CT and spirometry for adult females, in the presence of respiratory
symptoms
After initial evaluation the following surveillance has been suggested in patients 
with tuberous sclerosis:
24
• Renal ultrasonography every one to three years, replaced with renal MRI if 
multiple or large angiomyolipomas are present
• Cranial MRI every one to three years for children and adolescents
• Electroencephalography, if seizures are problematic
• Neurological, developmental and behavioural evaluations
• Echocardiography, if cardiac symptoms indicate
• Chest CT, if chest symptoms indicate
However, the value of performing ‘routine’ cranial and renal imaging in the absence of 
symptoms or pathology is debatable. An alternative approach is a clinical evaluation at 
regular intervals (e.g. annually) with a focus on neurological, renal, skin, pulmonary, 
cardiac, developmental and psychological problems, with investigations directed 
accordingly and interim assessment if clinical problems develop.
25
1.2 Clinical features of lymphangioleiomyomatosis (LAM)
LAM is a rare disorder, occurring almost exclusively in premenopausal women. The 
clinical features result from the accumulation of ‘LAM’ cells in the pulmonary 
interstitium and the lymphatic system and cystic degeneration of the lung, generally 
leading to progressive respiratory failure [18, 31].
Sporadic LAM (S-LAM) is a rare condition with a prevalence of approximately 1 in 
1,000,000 [32] in the whole population. However, LAM is much more common in 
patients with tuberous sclerosis (TSC-LAM). Radiological evidence of LAM is present 
in 40% of adult females with tuberous sclerosis although only 2-3% will develop 
symptoms of LAM [33, 34].
The disease tends to present between the menarche and menopause, with the mean age 
of onset being 34 years. Respiratory problems tend to dominate the clinical course, with 
the most common being progressive dyspnoea and pneumothorax [35-37]. Other 
respiratory problems seen include cough, haemoptysis, chyloptysis and chylous pleural 
effusions. Extrapulmonary manifestations of LAM are lymphadenopathy, 
lymphangioleiomyomas (large cystic masses which most commonly occur in the 
abdomen, retroperitoneum and pelvis), chylous acites and, in approximately half of 
patients, renal AMLs [38-40].
The differential diagnosis of LAM includes Langerhans’ cell histiocytosis, COPD 
(particularly a  1-antitrypsin related COPD), sarcoidosis, Sjogren syndrome, follicular 
bronchiolitis and lymphocytic interstitial pneumonitis, chronic hypersensitivity 
pneumonitis and Birt-Hogg-Dube syndrome.
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The chest radiograph is often normal in early disease but may show a pneumothorax or 
pleural effusion. The most common findings in established disease are reticulonodular 
shadowing and cysts or bullae with overexpansion of the lungs. The disease has a 
characteristic high resolution CT appearance with multiple thin-walled cysts scattered 
throughout the lung fields with normal intervening parenchyma.
Pulmonary function tests may be normal in early disease although the majority of 
patients have airflow obstruction with a decreased FEV1. The lung volumes are 
generally preserved and patients may have an increased total lung capacity (TLC) 
because of lung hyperinflation and an increase in residual volume may be seen because 
of air trapping. Poor gas exchange results in reduced diffusion capacity (DLCO) [36].
The gold standard for the diagnosis of LAM is a tissue biopsy of the lung or involved 
lymphatics. Tissue biopsy is not necessary to establish the diagnosis of LAM in patients 
with a characteristic chest CT appearance and other manifestations of the disease such 
as AMLs. All patients with LAM should undergo a careful examination for evidence of 
tuberous sclerosis.
Patients with sporadic LAM generally develop progressive airflow obstruction. In a US 
study of a cohort of over 300 LAM patients a mean decline of FEV1 of 75ml a year and 
of DLCO of 0.69 mL/min/mm Hg was reported [41]. A European study suggested that 
the forced FEV1 declined at a rate of 118mL per year [32]. There are no prospective 
studies on survival but retrospective data suggest the 10-year survival is in the order of 
55-71% [37]
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Current treatment options for LAM are limited. Two small retrospective studies have 
tried to assess the efficacy of progesterone, one showed a significant reduction in the 
rate of decline in DLCO in treated, compared with untreated, patients, the other showed 
no difference in lung function between treated and untreated patients [32, 42]. Lung 
transplantation is a potential option for patients with severe LAM (typically when FEV 1 
and/or DLCO are below 40% of predicted). In a retrospective series of 34 patients with 
LAM who underwent a lung transplant survival was 65% at five years [43].
1.3 Histopathology of AMLs and LAM
AMLs and LAM lesions are considered perivascular epithelioid cell (PEComa) 
tumours, mesenchymal tumours that share a histologically and immunohistochemically 
distinctive cell type, the perivascular epithelioid cell or PEC [44]. These cells are 
characterised by a perivascular location and a epithelial or spindle shape morphology, 
resembling smooth muscle cells with variable accumulation of lipid, which can mimic 
adiopocytes. PEComas contain blood vessels, in which the PECs appears to comprise 
the muscular wall [45]. Great variation in the relative proportion of epithlioid, spindle 
and lipid distended cells occurs. Immunohistochemically, PEComas express myogenic 
and melanocytic markers, such as gplOO, MelanA/Martl, micropthalmia transcription 
factor, and smooth muscle markers, including smooth muscle actin and, less commonly, 
desmin [45].
PECs are present in a group of lesions including AML, LAM tissue, clear-cell “sugar” 
tumor of the lung and extrapulmonary sites, clear-cell myomelanocytic tumor of the
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falciform ligament/ligamentum teres and abdominopelvic sarcoma of perivascular 
epithelioid cells.
AML is the commonest PEComa and occurs both sporadically and in association with 
tuberous sclerosis. Classic AMLs have a triphasic histology with tortuous blood vessels, 
myoid appearing PEC and lipid distended PEC [46]. Blood vessels with walls composed 
of PECs and vessels with normal smooth muscle walls are seen in AMLs [47].
In the lung, LAM consists of a proliferation of myoid appearing PECs distributed 
around bronchial lymphatics, interlobular septae and pleura. LAM of lymph nodes or 
the thoracic duct is characterised by perilymphatic proliferation of PECs [44].
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1.4 The genetic basis of tuberous sclerosis and LAM
1.4.1 TSC1 and TSC2
TSC1 (OMIM #605284) and TSC2 (OMIM #191092) were identified in 1997 and 1992, 
respectively, [48, 49] as the genes mutated in tuberous sclerosis. The TSC1 gene on 
chromosome 9 consists of 23 exons, the first two of which are untranslated and the 
second is alternatively spliced. Hamartin or TSC1, the protein product of TSC1 consists 
of 1164 amino acids. The TSC2 gene on chromosome 16 consists of 41 coding exons 
and a noncoding leader exon, of which exons 25, 26 and 31 are alternatively spliced. 
The protein product, tuberin, or TSC2 is a full length isoform of 1807 amino acids. A 
region spanning residues 1517-1674, encoded by exons 34-38 contains a GTPase 
activating domain. TSC2 also contains a calmodulin binding domain and an oestrogen 
receptor binding domain.
Studies of the TSC1 and TSC2 genes in patients with tuberous sclerosis have revealed a 
wide spectrum of mutations, but there are no particular regions within the genes in 
which mutations occur at a high rate. Tuberous sclerosis associated TSC2 mutations 
include missense, nonsense and frameshift deletions/insertions and splice junction 
mutations. Also, significant numbers of large (exonic and whole-gene) deletions have 
been reported [50-54]. TSC1 mutations in patients with tuberous sclerosis are primarily 
small deletions and insertions and nonsense mutations. Pathogenic TSC1 missense 
changes are rare. However, recent studies of TSC1 missense variants in bladder cancers 
[55] and in patients with TSC [56, 57] have shown that TSC1 amino acid substitutions 
can be pathogenic.
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Approximately 10-20% of patients who meet the diagnostic criteria for TSC do not have 
any identifiable mutations. These patients appear to have a distinct phenotype from 
patients in whom a mutation has been identified with a lower incidence of neurological 
features and renal findings than those with TSC2 mutations and a lower incidence of 
seizures but a higher incidence of both renal angiomyolipomas and pulmonary 
lymphangioleiomyomatosis compared with tuberous sclerosis patients 
with TSC1 mutations [58].
Mutations in TSC2 are about 5 times more common than mutations in TSC1 in the 
sporadic tuberous sclerosis population, whereas the ratio is approximately 1:1 in large 
families with multiple generations affected. Patients with mutations in TSC2 are more 
likely to have a higher number and/or more severe clinical features than those with 
mutations in TSC1 [51, 54].
1.4.2 Modulation of mTORCl and mTORC2 activity by TSC1/TSC2
The proteins encoded by TSC1 and TSC2 form a complex within cells. TSC1 stabilises 
TSC2, possibly by inhibiting its interaction with HERC1 ubiquitin ligase [59]. One of 
the best defined functions of the TSC1/TSC2 complex is in the regulation of mTOR, 
which in mammalian cells exists in two functionally distinct complexes, mTORCl and 
mTORC2.
mTORCl is a key mediator of multiple cell functions. TSC2’s GAP (GTPase-activating 
protein) domain stimulates the intrinsic GTPase activity of the small G-protein, Rheb, 
enhancing the conversion of the active GTP bound form of Rheb to the inactive GDP 
form. Rheb, when it is GTP-bound [60] and famesylated [61], activates mTORCl,
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possibly by inhibiting FKBP38, an endogenous inhibitor of mTOR [62]. In addition, 
Rheb-GTP stimulates phospholipase-Dl (PL-D1) to generate phosphatidic acid, a 
positive effector of mTORCl activation. Thus, loss of functional TSC1/2 leads to 
overactivation of mTORCl. The contribution of Rheb's regulation of PL-D1 and 
FKBP38 to mTORCl activation, relative to Rheb's direct binding to mTOR, remains to 
be fully defined.
Translationally controlled tumour protein (TCTP) has been suggested to act as a Rheb 
guanine nucleotide exchange factor (GEF) [63] but this has not been consistently 
demonstrated [64, 65].
The TSC1/TSC2 complex appears to also promote mTORC2 activation in a Rheb 
independent manner by an unknown mechanism [66].
1.4.3 Molecular pathology of AMLs and LAM
Mutation of both alleles of either TSC1 or TSC2 appears to be required for the formation 
of most lesions in tuberous sclerosis, consistent with the two-hit tumour suppressor gene 
model of Knudson [67]. Many second hit mutations are large deletions and LOH in 
either TSC1 or TSC2 has been reported in most tuberous sclerosis associated 
angiomyolipomas, SEGA’s and cardiac rhabdomyomas but only rarely in cortical tubers 
[68-70]. Haploinsufficiency may play a role in some of the pathology associated with 
tuberous sclerosis and it has also been suggested that inappropriate phosphorylation of 
TSC2 may mimic a second hit in brain and cardiac lesions [71-73].
Patients with sporadic LAM do not have germline mutations in TSC1 or TSC2. It has 
been suggested that histologically benign appearing LAM cells arise from a renal 
angiomyolipoma or an alternative unknown site and migrate to the lung in a process that
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has been termed ‘benign metastasis’ [74]. Genetic analysis has demonstrated identical 
TSC2 mutations and LOH at the TSC2 locus in paired lung LAM tissue and renal 
angiomyolipomas but not in normal lung tissue [75-77]. In samples from a patient with 
recurrent sporadic LAM post lung transplantation, the same mutation in TSC2 was 
found in LAM cells from both the native and transplanted lung [78]. LAM cells have 
been isolated from the circulatory system of patients with LAM, indicating that these 
migratory cells have the potential to survive in the circulation [79].
Evidence of mTORCl pathway activation is consistently seen in lung LAM tissue [80] 
and in angiomyolipomas [81] and other tuberous sclerosis related lesions [72, 82]
(Fig. 1).
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Figure 1: mTORCl pathway activation in human and mouse TSC-associated renal 
tumours
A
Immunohistochemical staining with an anti-phospho- ribosomal protein S6 antibody 
(Ser240/Ser244) o f (A) a renal angiomyolipoma from a patient with tuberous sclerosis 
showing phospho-S6-positive cells in the tumour (upper part o f section) and (B) 
phospho-S6-positive cells in a renal cell carcinoma (left) and scattered small cysts 
(right) from the kidney of a Tscl+/~ mouse. Figure courtesy o f Dr C. Bonnet (Institute 
of Medical Genetics, Cardiff University).
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Chapter 2: The pharmacology of sirolimus
2.1 Introduction
Sirolimus, (Rapamune, Wyeth Pharmaceuticals), is a macrolide antibiotic first 
discovered in 1975. It was isolated from a strain of Streptomyces hygroscopicus 
cultured from a soil sample from Rapa Nui, one of the Easter Islands in the South 
Pacific. Hence, the original name of the drug, rapamycin [83-85]. Sirolimus is used in 
clinical practice as an immunosuppressant in organ transplantation [86] and in drug 
eluting stents as an inhibitor of restenosis after angioplasty [87]. Analogues of 
rapamycin (rapalogs) are currently used for the treatment of renal cancer and mantle cell 
lymphoma [88].
Sirolimus forms an intracellular complex with the peptidyl-prolyl cis-trans isomerase 
FKBP12 [89]. This drug/receptor complex binds to mTOR at a location N-terminal to 
the kinase domain. Binding of FKBP12-sirolimus leads to inhibition of mTOR function 
in a poorly understood manner.
Sirolimus is available as 1 mg and 2 mg coated tablets or as a 1 mg/ml oral solution. In 
the context of renal transplantation the usual dosage regimen is a 6 mg oral loading dose 
followed by 2 mg once daily. When used with cyclosporin the dose is titrated to obtain 
whole blood trough levels of 4 to 12 ng/ml. As a single agent the sirolimus dose is 
adjusted to obtain whole blood trough levels of 12 to 20 ng/ml.
2.2 Pharmacokinetics
Following administration of the oral solution, sirolimus is rapidly absorbed, with a time 
to peak concentration of 1 hour in healthy subjects receiving single doses. The half-life
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in renal transplant patients was 62±16h. Pharmacokinetic parameters for sirolimus 
obtained from 19 renal transplant patients receiving cyclosporin, corticosteroids and 
daily doses of 2 mg sirolimus solution in a phase m  clinical trial, were; Cmax 12.2±6.2 
ng/ml, tmax 3.01±2.40h, AUCt, 158±70 ng-h/ml. Mean sirolimus whole blood trough 
levels were 7.2 ng/ml (range 4.0 to 11 ng/ml) [90].
2.3 Interactions with other medications
Sirolimus is extensively metabolised by the CYP3A4 isozyme in the intestinal wall and 
liver. Sirolimus is also a substrate for the multidrug efflux pump, P-glycoprotein, 
located in the small intestine. Strong inhibitors of CYP3A4 (such as ketoconazole, 
voriconazole, itraconazole, telithromycin and clarithromycin) decrease the metabolism 
of sirolimus and may markedly increase sirolimus levels. Strong inducers of CYP3A4 
(such as rifampicin or rifabutin) increase the metabolism of sirolimus and may 
markedly decrease sirolimus levels. Co-administration of sirolimus with strong 
inhibitors of CYP3A4 or inducers of CYP3A4 is not recommended. Grapefruit juice 
affects CYP3A4 mediated metabolism and should therefore be avoided [90].
2.4 Adverse reactions
The most commonly reported adverse drug reactions (occurring in >10% of patients) 
associated with sirolimus are thrombocytopenia, anaemia, pyrexia, hypertension, 
hypokalaemia, hypophosphataemia, urinary tract infection, hypercholesterolaemia, 
hyperglycaemia, hypertriglyceridaemia, abdominal pain, lymphocoele, peripheral 
oedema, arthralgia, acne, diarrhoea, oral mucositis, constipation, nausea, headache, 
increased blood creatinine, and increased blood lactate dehydrogenase (LDH) [90] 
(table 2).
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Table 2: Toxicities associated with sirolimus (adapted from sirolimus summary of 
product characteristics [90])
Class Very common Common Uncommon
( *1/10) ( >1/100 to <1/10) ( *1/1000 to 
<1/100)
Infections Urinary tract infection Sepsis
Pneumonia
Pyelonephritis
Fungal, viral, and 
bacterial infections
Neoplasms 
benign and 
malignant
Skin Cancer Lymphoma / post 
transplant
lymphoproliferative
disorder
Blood and 
lymphatic system 
disorders
Thrombocytopenia
Anaemia
Thrombocytopenic 
purpura/haemolytic 
uraemic syndrome
Leukopenia
Neutropenia
Pancytopenia
Metabolism and
nutrition
disorders
Hypokalaemia
Hypophosphataemia
Hypercholesterolaemia
Hyperglycaemia
Hypertriglyceridaemia
Nervous system 
disorders
Headache
Cardiac
disorders
Tachycardia Pericardial effusion
Vascular
disorders
Lymphocele Deep vein 
thrombosis
Pulmonary
embolism
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Hypertension
Respiratory, 
thoracic, and 
mediastinal 
disorders
Pneumonitis 
Pleural effusion 
Epistaxis
Pulmonary
haemorrhage
Gastrointestinal
disorders
Abdominal pain
Stomatitis
Diarrhoea
Constipation
Nausea
Pancreatitis
Hepatobiliary
disorders
Abnormal liver 
function tests
Skin and 
subcutaneous 
tissue disorders
Acne like rash
Musculoskeletal 
and connective 
tissue disorders
Arthralgia Osteonecrosis
Renal and 
urinary disorders
Proteinuria Nephrotic syndrome
General
disorders
Peripheral oedema 
Pyrexia
Impaired healing
Other
investigations
Blood lactate
dehydrogenase
increased
Blood creatinine 
increased
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Chapter 3: The mTOR pathway
3.1 Introduction
The ability to sense and integrate diverse signals is essential for cells to modulate 
physiological responses. Eukaryotic cells have the capacity to sense signals from their 
growth environment such as the availability of nutrients and also receive additional 
signals in the form of growth factors, cytokines and cell-adhesion molecules. A 
complex intracellular signalling network integrates the diverse inputs and directs 
appropriate cellular responses. The mTOR signalling pathway (Fig. 2) plays a central 
role integrating the growth factor, nutrient and stress signals in the control of multiple 
cellular functions, allowing a cell to balance catabolic and anabolic processes.
The serine/threonine kinase, mTOR, is a member of the phosphoinositide 3-kinase 
related kinase (PIKK) family, along with ATM, ATR, DNA-PKs and hSMGl. The 
domain structure of mTOR consists of multiple HEAT repeats (for Huntington, EF3, A 
subunit of PP2A, TOR) at the NH2 terminus domain, the FAT domain (FRAP-ATM- 
TRRAP), the FRB (FKBP12-rapamycin binding) domain, the kinase domain and 
another FAT domain close to the C-terminus.
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Figure 2: The TSC/mTOR signalling pathway
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Figure 2: mTORCl integrates multiple signals in the control of key cell processes.
In mammalian cells, mTOR exists in two functionally distinct complexes: mTOR 
complex 1 (mTORCl) and mTOR complex 2 (mTORC2). mTORCl is comprised of 
mTOR, Raptor (regulatory associated protein of mTOR), mLST8 (mammalian lethal 
with SEC 13 protein 8), also known as GpL, proline rich AKT substrate 40kDa 
(PRAS40) and DEP-domain containing mTOR-interacting protein (Deptor) [61, 91-97]. 
Within mTORCl, Raptor contributes to mTOR substrate specificity by binding to 
substrates via TOR signalling [61, 91-98] motifs on the proteins. The role of mLST8 is 
unclear whilst PRAS40 and Deptor have been characterised as negative regulators of 
mTORCl. The best characterised mTORCl substrates are the ribosomal protein S6 
kinases (S6K1 and S6K2) and the eukaryotic initiation factor 4E-binding proteins (4E- 
BP1, 4E-BP2 and 4E-BP3). The second mTOR containing protein complex, mTORC2, 
is comprised of 6 different proteins, several of which are common to mTORCl and
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mTORC2: mTOR, rictor (rapamycin-insensitive companion of mTOR), mammalian 
stress-activated protein kinase interacting protein (mSINl), protein observed with 
Rictor-1 (PROTORI), mLST8/Gbl and Deptor [91, 92, 94, 99-105].
3.2 Functions of the TSCl/TSC2/mTORCl pathway
3.2.1 Control of cell growth, macromolecule synthesis and metabolism
Promotion of cell growth (an increase in cell mass) is an evolutionary conserved 
mTORCl function which extends to the control of organ and organism size [106, 107]. 
In model systems loss of TSC1/2 is associated with an increase in cell and organ size 
[108-110] and treatment with sirolimus results in a reduction in cell size [106].
mTORCl plays a key role in the regulation of the synthesis of macromolecules such as 
proteins and lipids which are required for cell growth [111]. mTORCl regulates the 
activity of the translational machinery as a whole and also specifically controls the 
translation of a subset of messenger RNAs (mRNAs) that are thought to promote cell 
growth and proliferation. mTORCl regulates cap-dependent translation by 
phosphorylating 4E-BP1 preventing its binding to eIF4E [112]. Phosphorylation of 
S6K1 by mTORCl leads to increases mRNA synthesis, cap-dependent translation and 
elongation and translation of ribosomal proteins. The activation of mTORCl also leads 
to promotion of ribosomal biogenesis by stimulating the transcription of ribosomal 
RNA [113].
mTORCl regulates glycolysis, sterol and lipid biosynthesis and the pentose phosphate 
pathway [111]. mTORCl activates sterol regulatory element binding protein 1 
(SREBP1) and peroxisome proliferator-activated receptor-y (PPARy), two transcription
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factors that control the expression of genes encoding proteins involved in cholesterol, 
fatty acid, triglyceride and phospholipid synthesis. Inhibition of mTOR with sirolimus 
reduces the activity of PPARy and constitutive activation of mTORCl via loss of TSC2 
increases PPAR-y activity and expression of SREBP1, promoting adipogenesis [114, 
115].
An unbiased metabolomic screen in Tscl or 2 deficient MEFs showed an increase in the 
intermediates of glycolysis and the pentose phosphate pathway [111]. Much of the 
glycolytic response downstream of mTORCl is mediated by increased HIFla activity. 
However, cells lacking TSC2 have reduced membrane localization of the glucose 
transporters Glutl, Glut2, and Glut4 following growth factor stimulation [116]. In 
concordance with this, LAM tissue and tuberous sclerosis associated AMLs do not 
exhibit abnormal uptake of [18F]2-fluoro-2-deoxyglucose during PET scanning [117].
3.2.2 Control of stress responses, apoptosis and autophagy
Autophagy is a catabolic pathway for the degradation of cellular components, including 
organelles and long-lived proteins via regulated lysosomal degradation. Autophagy is 
up-regulated in mammalian cells under certain conditions of cellular stress such as 
nutrient restriction and hypoxia. Under stress the degradation of organelles and proteins 
through autophagy provides substrates to sustain anabolic processes and energy 
production. Activation of mTOR inhibits autophagy while inhibition of mTOR with 
sirolimus induces autophagy. A mechanism by which mTORCl controls autophagy is 
via phosphorylation of autophagy-related gene 13 (Atgl3), focal adhesion kinase family 
interacting protein of 200kDa (FIP200) and the mammalian Atgl homologues unc-51- 
like kinase 1 and 2 (ULK1 and ULK2). Binding of A tgl3 stabilises ULK and facilitates
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the phosphorylation of FIP200 by ULK leading to an activation of autophagy [118]. 
TSC1-/- MEFs exhibit abrogated autophagy which remains sirolimus inducible [119].
mTOR has a complex effect on apoptosis, having pro and anti-apoptotic effects 
depending on factors such as cell type and environment [120, 121]. TSC1/2 deficient 
cells exhibit increased sensitivity to some apoptosis inducing stimuli e.g. glucose 
deprivation [122-124] with sirolimus having a protective effect but decreased sensitivity 
to other apoptotic inducing stimuli e.g. hypoxia [125]. The sensitisation of TSC1/2 
deficient cells to some proapoptotic stimuli may be explained by inhibition of AKT 
activity by a negative feedback mechanism induced by the hyperactive mTORCl or as a 
result of inflexibility of metabolism and stress responses. The resistance of TSC1/2 
deficient cells to specific apoptotic stimuli may be attributable to increased HIFla 
activity, Mcl-1 expression, sustained glycogen synthase kinase 3 beta inhibition [126] 
or aberrant AMPK [127] and p27 function [128, 129]. Loss of TSC2 in a murine c-myc 
driven lymphoma model led to accelerated oncogenesis due to defective apoptosis 
despite compromised AKT phosphorylation [130] and TSC1/2 deficient cells exhibit 
resistance to anoikis [131].
3.2.3 Cell cycle progression
In mammalian cells mTORCl promotes transition from G1 to S and entry into mitosis. 
In many cell types these transitions are blocked by sirolimus. Sirolimus prevents the 
mitogen induced decrease in levels of p27, a cyclin-dependent kinase inhibitor, and 
decreases levels of cyclin D1 and D3. Phosphorylation of Raptor during mitosis 
facilitates cell cycle transit through G2/M, with the cyclin-dependent kinase 1 
(cdkl/cdc2) and glycogen synthase kinase 3 (GSK3) pathways probably being the two
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mitosis-regulated protein kinase pathways involved [132]. CDK1 also phosphorylates 
TSC1 during G2/M [133]. Mitotic phosphorylated raptor promotes translation by 
internal ribosome entry sites on mRNA during mitosis and is associated with sirolimus 
resistance [134].
The effect of activated mTOR signalling on cell cycle progression may be context 
dependent. Thus, while increased mTOR signalling promotes proliferation under 
favourable conditions, increased mTOR signalling can promote senescence under some 
conditions in the context of conflicting signals [135, 136]. Depending on the cell type 
and other factors, p53 activation can result in apoptosis or reversible cell cycle arrest 
(quiescence) or irreversible cell cycle arrest (senescence). Activation of p53 increases 
the expression of several genes, including TSC2 whose protein products inhibit mTOR 
activity. In some cell lines activation of p53 and the consequent inhibition of mTOR 
leads to quiescence. Tsc2(-/-) MEFs display early senescence that is rescued by loss of 
p53 [137]. However, if Tsc2 is knocked down by siRNA, activation of p53 leads to 
senescence [138].
3.2.4 Mitochondrial biogenesis
Mitochondrial biogenesis and metabolism are both regulated by mTORCl. The 
expression of a number of genes involved in mitochondrial biogenesis, cellular 
mitochondrial DNA content mitochondrial membrane potential, oxygen consumption, 
and ATP synthetic capacity correlates with mTORCl activity [139, 140]. Tsc2'/' MEFs 
have increased mitochondrial DNA content, oxygen consumption and expression of 
genes encoding mitochondrial components and transcription factors which promote 
mitochondrial biogenesis, all of which are down regulated by sirolimus [140].
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3.2.5 Stem cell maintenance
Excessive mTORCl activity leads to stem cell depletion, which is at least in part 
mediated by the induction of stem cell senescence and can be reversed by sirolimus 
[141, 142]. Conditional Tscl deletion in the haematopoietic stem cells in mice leads to a 
reduction in the self renewal of haematopoietic stem cells and decreased 
haematopoiesis, which can be rescued by sirolimus [143, 144]. In the Drosophila ovary, 
disruption of either the Tscl or Tsc2 gene in the germline stem cell leads to precocious 
differentiation and loss. The germline stem cell loss can be rescued by treatment with 
sirolimus [145]. Restriction of stem cell depletion may partially account for the increase 
in longevity seen in mice following treatment with sirolimus [146].
3.3.6 Cell motility
The evidence regarding the role of the TSC genes in cell motility is conflicting; with some 
studies suggesting loss of TSC 1/2 promotes motility [147-149] and others suggesting TSC 1/2 
loss inhibits motility [150]. This may reflect cell type dependent effects or variation in assay 
methods used.
3.2.7 Epithelial-mesenchymal transition
TSC1/2 deficient cells exhibit a reduction in plasma membrane located E-cadherin, in a 
sirolimus sensitive manner, and consequently reduced cell-cell adhesion and loss of 
contact inhibition. Non adherent TSC1/2 deficient cells acquire the molecular and 
functional characteristics of epithelial-mesenchymal transition, rendering them resistant 
to anoikis [131].
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3.2.8 mTORCl or sirolimus insensitive functions of TSC1/2
A number of other functions of the TSC1/TSC2 complex appear to be mTORCl 
independent or sirolimus insensitive. The TSC1/TSC2 complex inhibits Wnt induced (3- 
catenin transcriptional activity and promotes the degradation of p-catenin [151]. AMPK 
is activated in TSC2-null cells via Rheb independently of its regulation of mTORCl 
signalling [152]. Loss of TSC2 leads to up regulation of notch signalling in a sirolimus 
insensitive manner [153]. TSC2 interacts with the ezrin-radixin-moesin family of actin- 
binding proteins Rho and Racl to regulate cell adhesion and cell motility, as well as 
influencing the actin cytoskeleton, in a sirolimus insensitive manner [154, 155]. The 
tuberous sclerosis proteins also regulate the formation of primary cilia via a sirolimus 
insensitive mechanism [156]. Additionally, Rheb inhibits B-Raf and C-Raf kinase 
activity [157, 158] and regulates the interaction of FKBP38 with Bcl-2 and Bcl-XL in a 
sirolimus insensitive manner [159].
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3.2.9 The regulation of the mTORCl/TSC pathway
mTORCl acts as a signal integrator for four major regulatory inputs - growth factors, 
energy, oxygen and amino acids.
3.2.10 Growth factors
Growth factors stimulate mTORCl through the activation of intracellular signalling 
pathways. For example, the binding of insulin to its cell surface receptor promotes the 
tyrosine kinase activity of the receptor, the recruitment of insulin receptor substrate 1 
(IRS1), the production of phosphotidylinositol (3,4,5)-triphosphate [Ptdlns (3,4,5)P3] 
and the recruitment and activation of AKT at the plasma membrane. Activated AKT 
phosphorylates several downstream substrates and stimulates mTORCl through two 
interconnected mechanisms, inhibiting both PRAS40 and TSC2. AKT directly 
phosphorylates TSC2 on a number of residues, including Ser939, Ser981 and Thrl462, 
inhibiting the ability of TSC2 to repress mTORCl activation, possibly by disruption or 
increased degradation of the TSC1/TSC2 complex or by altered subcellular localisation, 
due to altered interaction with the cytosolic anchor protein 14-3-3. TSC2 bound by 14- 
3-3 in response to AKT phosphorylation is sequestered away from membrane-bound 
TSC1 and Rheb [160].
PRAS40 has been described as either an mTORCl inhibitor, mTORCl substrate or 
both. Activated AKT phosphorylates PRAS40, resulting in the dissociation of PRAS40 
from mTORCl, possibly mediated by the binding of 14-3-3 to phosphorylated PRAS40 
[161-163].
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Mitogen activated Ras-ERK signalling has been shown to trigger the activation of 
mTORCl signalling via ERK- and RSK-dependent phosphorylation of TSC2 at Ser664 
and Serl798 respectively [72, 164]. RSK also directly targets the mTORCl complex by 
phosphorylation of Raptor and directly promoting mTORl kinase activity [165].
3.2.11 Energy
Depletion of intracellular energy leads to inhibition of mTORCl. The energy status of a 
cell is signalled to mTORCl by AMP-activated protein kinase (AMPK), a master sensor 
of intracellular energy status. When intracellular ATP levels decline and AMP levels 
increase, the binding of AMP to AMPK primes it for activation by upstream kinases 
including the tumour suppressor LKB1 [166]. Activated AMPK then interacts with 
multiple cellular metabolic targets to maintain intracellular ATP homeostasis by up- 
regulation of catabolic processes which generate ATP and down regulation of ATP 
consuming processes.
AMPK inhibits mTORCl in two ways. AMPK phosphorylates TSC2 on at least two 
residues (Serl387 and Thrl27), which may activate its GAP activity [123]. 
Additionally, AMPK directly phophorylates Raptor inhibiting mTORCl kinase activity 
[167]. The AMPK dependent phosphorylation at Serl387 primes TSC2 for further 
phosphorylation by glycogen synthase kinase 3(3 (GSK3(3) within the context of Wnt 
signalling. This provides an opportunity for cross talk between Wnt signalling and 
energy sensing pathways. Wnt which inhibits GSK3|3 appears to activate mTORCl by 
overcoming AMPK mediated activating effects in the TSC1-TSC2 complex [168].
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The transcription factor REDD1 (regulated in development and DNA damage response) 
is induced in response to energy stress, hypoxia, DNA damage, glucocorticoids and 
oxidative stress. A REDD1 mediated decrease in mTORCl signalling in response to 
hypoxia is TSC2 dependent and can be inhibited by direct activation of AMPK by AMP 
mimetics. REDD1 has been shown to bind to 14-3-3 proteins and may activate the 
TSC1-TSC2 complex by releasing TSC2 from its association with inhibitory 14-3-3 
proteins[169]. TSC 1/2 deficient MEFs are highly susceptible to apoptosis upon glucose 
starvation with sirolimus having a protective effect [123, 124].
3.2.12 Oxygen levels
Hypoxia inhibits mTORCl by a number of mechanisms. As oxygen is required for 
aerobic ATP production via mitochondrial oxidative phosphorylation, hypoxia causes 
energy stress and AMPK mediated phosphorylation and activation of TSC1/TSC2 
[170]. Hypoxia induced HIF1 activity leads to induction of REDD1 and hence of 
TSC1/TSC2 complex activity [171, 172]. Hypoxia also results in TSC1/2 independent 
inhibition of mTORCl via the protein promyelocytic leukemia (PML) [173] which 
negatively regulates the association of mTOR with Rheb and Bnip3 which mediates a 
decrease in Rheb GTP levels [174].
In response to hypoxia, TSC deficient cells fail to down regulate mTORCl activity, 
exhibit an exaggerated and prolonged increase in HIF activity, continue to proliferation 
at a rate much higher that their wild type counterparts in a manner that is, at least 
partially, insensitive to sirolimus and are protected against hypoxia induced apoptosis 
[125, 169, 171, 172, 175].
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3.2.13 Amino acids
Amino acids, particularly the branched chain amino acid leucine, represent a strong 
signal that positively regulates mTORCl. The primary amino acid sensor is unknown 
but candidate downstream mediators have emerged, including the Ste20 (sterile20)- 
related kinase mammalian protein kinase, MAP4K3 (mitogen-activated protein kinase 
kinase kinase kinase 3) [176] and hVps34 (human vacuolar protein sorting mutant 34) 
[177]. Intracellular amino acid activation of mTORCl is known to be independent of 
TSC1/2 as the mTOR remains sensitive to amino acid deprivation in cells that lack 
TSC1 or TSC2 [177]. A protein complex called Ragulator, which interacts with Rag 
GTPases, is necessary for amino acid dependent mTORCl activation and mediates a 
translocation to lysosomal membrane surfaces. [178-180].
3.2.14 Other regulators of TSC1/2 and of the mTOR pathway
In addition to the key signals described above, other cellular conditions and signalling 
pathways regulate mTORCl activity including genotoxic stress, oxidative stress, 
endoplasmic reticulum stress, phosphatidic acid and cytokines. Over 50 proteins have 
been shown to interact with TSC1 or TSC2 or both and the functional significance of 
many of these interactions remains to be fully elucidated [181, 182]. TSC1 contains 
phosphorylation sites for the kinases Cdkl [133], GSK3 [151] and IKKbeta [183]. 
TSC2 is phosphorylated by Erk [72], Akt [184-186], GSK3 [168], DAPK1 [187], the 
p38 activated kinase MK2 [188], AMPK [123], RSK1 [164] and FAK [189].
Genotoxic stress reduces mTORCl activity by a number of mechanisms. Activation of 
p53 in response to DNA damage activates AMPK which in turn activates TSC2 [190]. 
Additionally, p53 negatively regulates mTORCl by increasing the transcription of
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PTEN and TSC2 [190, 191]. Oxidative stress in the form of reactive oxygen species 
leads mTORCl repression due to ATM mediated activation of TSC2 via LKB1/AMPK 
[192].
The endoplasmic reticulum is an organelle involved in the folding and post-translational 
modification of proteins, as well as calcium and sterol lipid biosynthesis. A number of 
physiological and pathological stimuli can interrupt the protein folding process and 
subsequently cause accumulation of unfolded or misfolded proteins in the ER - a 
condition referred to “ER stress”. The ER stress response is a series of coordinated 
cellular responses to reduce ER stress but in conditions where ER stress is prolonged or 
excessive cell death results [193]. ER stress down regulates mTORCl activity and 
TSC1/2 deficiency leads to a truncated ER stress response and increased sensitivity to 
ER stress inducing agents, which is not relieved by sirolimus [119, 194-196].
Phosphatidic acid (PA) is generated by phospholipase D mediated hydrolysis of 
phosphatidylcholine. PA binds to the FKBP12-rapamycin binding domain of mTOR in 
a manner that is competitive with FKBP12-rapamycin [197] and is required for 
formation of mTORCl and mTORC2 complexes [198]. Inflammatory mediators can 
induce mTORCl activity. The pro-inflammatory cytokine tumour necrosis factor a  
(TNFa) stimulates mTORCl signalling through IKKP mediated inhibition of TSC1- 
TCS2 by phosphorylation of TSC1 at Ser487 and Ser511 [183].
TSC2 binds to and is phosphorylated by DAPK1 leading to mTORCl inhibition [187]. 
DAPK plays an important role in a diverse range of signal transduction pathways 
involved in cell proliferation, apoptosis, autophagy and immune responses. DAPK
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activity is responsive to growth factors, TNF-a, TGF-(3, IFN-y, DNA damage and 
transformed oncogenes [199].
TSC2 is phosphorylated and inhibited by FAK, a mediator of integrin signalling, 
suggesting a role for TSC2 in the regulation of mTOR signalling by cell adhesion [189]. 
FIP200 binds to and inhibits the kinase domain of FAK and also binds TSC1 [200].
Primary cilia are cell surface organelles that act as sensory antennae for various input 
signals. Bending of the cilium promotes relocalization of LKB1 to close proximity to its 
substrate AMPK, whose activation inhibits mTORCl signaling [201]. PC-1, the product 
of PKD1, regulates the cellular localisation of TSC2 [202]. Activation of mTORCl is 
seen in several rodent models of polycystic kidney disease and in renal cysts from 
humans with autosomal dominant polycystic kidney disease (ADPKD) [156, 203, 204]. 
Treatment with sirolimus has been shown to alleviate the ADPKD phenotype in murine 
models [205-207]
TSC2 is inactivated by ubiquitinisation and subsequent degradation. TSC2 is 
ubiquinated by the putative E3 ubiquitin ligases HERC1[59], PAM [208] and E6AP 
[209].
The mTOR pathway is regulated by a number of tumour suppressor genes associated 
with tumour predisposition syndromes. Loss of NF1, PTEN, LKB1 and BHD activity is 
associated with up regulation of mTORCl in cell culture, animal models and in tumours 
derived from patients with germline mutations in these genes. Sirolimus abrogated cell 
growth in cell culture and animal models of neurofibromatosis typel, Cowden’s disease,
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Peutz-Jeghers syndrome and Birt-Hogg-Dube syndrome and is currently being 
investigated in clinical trials in these conditions [210-221]. (ClinicalTrials.gov 
Identifiers -NCT01031901, NCT00634270, NCT00722449, NCT00971789,
NCT00811590, NCT00722449, NCT00971789).
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3.2.15 mTORC2
In contrast to mTORCl, for which many regulatory signals and cellular functions have 
been defined, relatively little is known about mTORC2. The best characterised function 
of mTORC2 is the phosphorylation of AKT on Ser473, leading to its activation [222, 
223].
mTORC2 also phosphorylates SGK1 (serum- and glucocorticoid-induced protein kinase
1) [224], regulates the phosphorylation of PKCa (protein kinase Ca) [223] and has 
been suggested to influence cell morphology and cytoskeleton reorganisation, through 
the Rho family small GTPases, including Rho, RAC and Cdc42 [100, 101]
The signalling pathways that regulate mTORC2 are not well characterised. Growth 
factors increase mTORC2 kinase activity and AKT phosphorylation at Ser473 [66, 222, 
225]. PtdIns(3,4,5)P3 can directly stimulate intrinsic mTORC2 kinase activity [226]. 
The TSC1/TSC2 complex, whilst inhibiting mTORCl signalling, promotes mTORC2 
activity. Thus, loss of the TSC1-TSC2 complex results in elevated mTORCl signalling 
and attenuated mTORC2 signalling. Loss of mTORC2 activity in cells lacking the 
TSC1-TSC2 complex, coupled with mTORCl-mediated feedback mechanisms, leads to 
strong attenuation of the growth factor-stimulated phosphorylation of AKT on S473 
[66]. mTORC2 substrates are affected by loss of the TSC1-TSC2 complex in cell 
culture models and kidney tumours from both Tsc2 (+/-) mice and tuberous sclerosis 
patients [227].
3.2.16 Feedback loops in the mTOR pathway
Intracellular signalling pathways are regulated by crosstalk and feedback mechanisms. 
A number of feedback loops affecting mTOR signalling have been described. One of
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the best characterised is inhibition of the PI3K pathway by mTORCl. Activation of 
mTORCl induces a negative feedback loops that attenuates signalling through the 
PI3K/Akt pathway, mediated by the phosphorylation and inhibition of IRS-1 by S6K 
[228, 229]. Functionally similar loops mediate the inhibition of PDGFR [230] and the 
ERK/MAPK [231] pathway in response to mTOR activity.
Tsc2-/~ MEFs exhibit mTORCl activation and attenuated signalling associated with 
PDGFR down regulation [137] and S6K1 mediated down regulation of insulin-/insulin- 
like growth factor receptor substrate 1 (IRS-1) [228] and are strongly defective in 
growth factor (insulin and IGF) stimulated PI3K-Akt signalling [137, 232-235]. The 
baseline and serum stimulated activation of Akt is markedly reduced in Tsc2~l~ MEFs 
and heterozygous Tsc knockout mouse models can be restored by treatment with 
sirolimus [228, 236, 237]. Inhibition of mTORCl signalling by sirolimus and other 
rapalogs reduced the feedback inhibition of Akt in a range of cancer cell lines in vitro as 
well as in cancer tissue derived from patients under treatment [238-241].
These negative feedback loops may have a number of consequences for tuberous 
sclerosis pathology and the therapeutic use of mTOR inhibitors. The benign nature of 
tumours in TSC may be partly due to inhibition of pro-survival pathways. It has been 
suggested that treatment with sirolimus may be attenuated by up regulation of these and 
other pathways, or even that malignant progression could be promoted.
3.2.17 Mechanism of action of sirolimus
mTORCl is acutely sensitive to sirolimus but not all mTORCl outputs are sirolimus 
sensitive [242-246]. The mechanism by which sirolimus inhibits mTORCl remains to 
be completely defined but sirolimus weakens the interaction between mTOR and
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Raptor [247] and reduces mTORCl intrinsic kinase activity [248]. mTORC2 is not 
acutely sensitive to sirolimus but prolonged treatment with the drug can, in some cell 
types, inhibit mTORC2 activity, possibly by sequestering mTOR in inhibited mTOTCl 
complexes [249] and suppressing the phosphorylation of Akt on Ser473. Moreover, 
high concentrations of sirolimus also block mTORC2 activity [250].
The mechanism by which sirolimus exerts effects may depend on the cell type and the 
mutation spectra present. In some cell lines sirolimus induces apoptosis but in others the 
effect is predominantly cytostatic, possibly mediated by inhibition of cell cycle 
progression at Gl. Additionally, in in vitro or in vivo models, mTOR inhibitors have 
also been demonstrated to decrease cell size, induce autophagy, promote senescence, 
inhibit angiogenesis, reduce motility, and selectively target stem cells (reviewed in 
[251-253]).
Recently developed small molecular ATP competitive mTOR kinase domain inhibitors 
inhibit both mTORCl and mTORC2 ( e.g. PP242 and PP30 [243], Ku-0063794 
[244],Torin [245] and WAY-600, WYE-687, and WYE-354 [246]). These drugs block 
the phosphorylation of Akt at Ser473 and inhibit cell proliferation more completely than 
sirolimus in a manner that is at least partially dependent on suppression of sirolimus 
resistant functions of mTORCl involved in cap-dependent translation and suppression 
of autophagy.
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Chapter 4: Preclinical and clinical studies of mTOR inhibition in 
tuberous sclerosis and lymphangioleiomyomatosis
4.1 Studies in model systems
The potential efficacy of sirolimus in TSC 1/2 deficient cells has been demonstrated in 
preclinical in vitro and in vivo models. In cell culture Tscl-I- and Tsc2-I- MEFs show up 
regulation of mTORCl activity and have a proliferative advantage over their wild type 
counterparts. Sirolimus has been shown to normalise deregulated mTOR signalling in 
cells that lack TSC1 or TSC2 [108, 137, 155, 184, 185, 254] and to reverse their 
proliferative advantage [137, 232].
The Eker rat carries a germline mutation in the TSC2 gene [255]. Spontaneous renal 
cortical epithelial tumours and pituitary adenomas occur in these animal due to biallelic 
inactivation of Tsc2 [256] and these tumours exhibit strong immunostaining for 
phospho-S6 [257]. Kenerson et al. administered sirolimus intraperitoneally to 12 month 
old Eker rats for 3 days. This was associated with reduced phosphorylation of S6, 
induction of apoptosis and decreased cellular proliferation in the renal tumours [257]. In 
a follow up study [258] Eker rats were treated with sirolimus for a longer time period 
(48 days) and most renal tumours underwent a >90% volume regression.
In transgenic mouse models of tuberous sclerosis sirolimus or rapalogs reduced renal 
tumour growth, associated with decreased cell proliferation and increased apoptosis. 
Similarly, in TSC2 deficient xenograft nude mouse models sirolimus or rapalogs 
reduced tumour growth [259-264].
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Mouse models also suggest that aspects of cognitive function and seizures in tuberous 
sclerosis can be improved by sirolimus. mTOR signalling appears to be required for 
molecular and cellular aspects of learning and for the encoding and recall of spatial and 
auditory memory [265-269]. Administration of rapamycin to wild-type rodents impaired 
long-term spatial [267] and auditory recall memory [266]. In contrast, mTOR inhibition 
did not influence recognition memory, motor or sensory systems in wild-type rodents 
[268].
Studies in heterozygous Tscl and Tsc2 mouse models have shown the presence of 
cognitive deficits in the absence of structural brain lesions or seizures [270, 271]. Both 
Tsc 1+1- and Tsc2+/~ mice show deficits in hippocampal dependent learning and 
memory, including deficient spatial learning and abnormalities in contextual fear 
conditioning. Additionally, Tscl+I- mice displayed deficits in social behaviour. These 
findings support a model in which haploinsufficiency for the TSC genes leads to 
aberrations in neuronal functioning resulting in impaired learning and social behaviour. 
Short term (3-5 days) treatment of Tsc2+I~ mice leads to a reversal of hippocampal- 
dependent learning deficits.
Mice with conditional deletion of Tscl in neurones have been generated, using either a 
Synapsin-I or a aCaMKII promoter to drive Cre recombinase. The Synapsin-I KO mice 
exhibited brain enlargement, largely due to neuronal hypertrophy, which was 
accompanied by astrogliosis, compromised survival and abnormal neurological findings 
and seizures. Sirolimus normalised brain weight and aspects of neuronal morphology 
and was associated with increased survival [272]. Sirolimus substantially increased
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survival of Tsclcc-aCaMKH-Cre mice, decreasing brain enlargement and improving 
aspects of the neurological phenotype [271].
A mouse model with conditional inactivation of the Tscl gene in glial cells developed 
progressive epilepsy, encephalopathy and decreased survival associated with 
progressive astrogliosis, increased brain size, and abnormal neuronal organization. 
Early treatment with sirolimus, before the development of seizures prevented, the 
development of epilepsy and improved survival. Late treatment with sirolimus after the 
development of seizures suppressed seizures and prolonged survival [273].
4.2 Clinical studies
Case reports have suggested that sirolimus induced reduction in the size of AMLs [274, 
275], astocytomas [276, 277] and facial angiofibroma [278] in tuberous sclerosis and in 
sporadic LAM.
Bissler at al. conducted a 24 month, nonrandomised trial to determine if sirolimus 
reduced angiomyolipoma volumes in patients with tuberous sclerosis or sporadic LAM 
[279] Patients received sirolimus for 1 year and were followed for an additional year 
after the therapy had stopped. The primary endpoint was angiomyolipoma volume at 1 
year, as assessed by renal MRI. Secondary endpoints included AML volume at 2 years 
and lung function measurements.
Twenty five patients were enrolled (7 with TSC only, 6 with sporadic LAM and 12 with 
TSC associated LAM). The mean (±SD) angiomyolipoma volume at 12 months was 
53.2±26.6% of the baseline value and at 24 months was 85.9±28.5% of the baseline 
value. After one year in patients with lymphangioleiomyomatosis, the mean FEVi
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increased by 118±330 ml, the mean FVC increased by 390±570 ml and the mean 
residual volume decreased by 439±493 ml, as compared with baseline but there was no 
change in DLCO. One year after sirolimus was discontinued, the mean FEVi was 
62±411 ml above the baseline value, the FVC was 346±712 ml above the baseline value, 
and the residual volume was 333±570 ml below the baseline value.
Figure 3: Change in AML volume during the trial of Bissler et al [279] (taken from 
manuscript)
120
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On Sirolimus Off Sirolimus
Time in months
AMLs were assessed with abdominal magnetic resonance imaging, and volumetric 
analysis was performed at baseline and at 2,4, 6, 12, 18, and 24 months. The AML 
volume is expressed as a percentage o f the baseline size. The dashed line represents 
70% of the baseline value;
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The use of sirolimus as an experimental treatment for brain tumours in tuberous 
sclerosis has been reported for four patients with SEGAs and one with pilocytic 
astrocytoma, ranging in age from 3 to 21 years [276]. Blood sirolimus levels were 
between 5-15 ng/ml and the duration of treatment was 2.5-20 months. Prior to entry 
into the study all lesions demonstrated growth and on treatment all exhibited regression 
and in one case necrosis (as assessed by MRI). In one patient interruption and then 
resumption of sirolimus therapy was mirrored by regrowth then further regression of the 
tumour.
Krueger et al performed a phase 13 trial of the rapalog everolimus as a treatment for 
SEGAs [280]. The trial enrolled 28 patients of age 3 and over. The primary efficacy end 
point was the change in volume of SEGAs between baseline and 6 months with 
everolimus given orally, at a dose to achieve a trough concentration of 5 to 15 ng per 
millilitre. A reduction of at least 30% was seen in 21 patients (75%) and of at least 50% 
in 9 patients (32%). Marked reductions were seen within 3 months and were sustained. 
Of the 16 patients for whom 24 hour video electroencephalography data were available, 
seizure frequency for the 6-month study period decreased in 9, did not change in 6, and 
increased in 1. Single cases of grade 3 treatment-related sinusitis, pneumonia, viral 
bronchitis, tooth infection, stomatitis, and leukopenia were reported.
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Chapter 5: A phase II trial of sirolimus as a therapy for renal 
angiomyolipomas in patients with tuberous sclerosis or sporadic 
lymphangioleiomyomatosis
5.1 Study aims/objectives
The primary aim of this study was to determine if sirolimus induces regression of renal 
angiomyolipomas (AMLs) in persons with tuberous sclerosis complex (TSC), or 
sporadic lymphangioleiomyomatosis (LAM). Secondary aims were to assess its safety 
in these patients and determine whether sirolimus therapy affects respiratory function 
test results in LAM or the results of cognitive testing in TSC.
5.2 Study approval
The study protocol was approved by a multi-centre research ethics committee (Thames 
Valley MREC) and by institutional review boards of the participating institutions. The 
study was conducted according to the UK Human Use (Clinical Trials) Regulations 
2004, the Directive 2001/20/EC of the European Parliament and the Declaration of 
Helsinki and its amendments. The trial was registered with European Clinical Trials 
database (EudraCT number 2004-00420-33), the Medicines and Healthcare products 
Regulatory Agency (CTA number 21323/0002/001-0001) and ClinicalTrials.gov 
(identifier:NCT00490789). The trial was sponsored by Cardiff University (sponsor 
number UW CM001).
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5.3 Participating centres
The study was conducted at University Hospital of Wales, Cardiff; the City Hospital, 
Nottingham; The Royal Sussex Hospital, Brighton and Zurich University Hospital, 
Zurich.
5.4 Inclusion and exclusion criteria
Eligible patients had to:
• have a clinically definite diagnosis of tuberous sclerosis (modified Gomez 
criteria) or sporadic LAM (biopsy-proven or compatible high resolution chest 
CT scan and respiratory function tests.);
• be between 18 and 65 years old;
• have one or more renal angiomyolipomas of at least two centimetres or 
greater in largest diameter;
• have adequate renal function: glomerular filtration rate > 40 ml/min (*);
• be competent to give informed consent;
• if female, have documentation of negative pregnancy test prior to enrolment;
• use an effective form of contraception, whilst taking sirolimus and for twelve 
weeks after stopping the drug (**);
Patients were excluded from the study if they:
• had a significant haematological or hepatic abnormality (transaminase levels > 
150 i.u./L serum albumin < 30 g/L, haematocrit< 30%, platelets < 100,000/
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mm^, adjusted absolute neutrophil count < 1,500/mm^, total WBC < 3,000/ 
mm3);
• had greater than 1 g proteinuria daily (***);
• had uncontrolled hyperlipidaemia (****);
• had embolisation for AML(s) within the preceding 6 months;
• had a renal haemorrhage within the preceding year or who had a renal
haemorrhage at any time previously and had a known conservatively managed 
renal aneurysm(s) greater than 10mm.);
• were pregnant or breastfeeding;
• had multiple bilateral AMLs, where individual lesions could not be 
distinguished;
• were unable to walk 100 metres on the flat;
• continuously required supplemental oxygen;
• had or were being considered for organ transplant;
• had intercurrent infection at initiation of Sirolimus;
• had surgery within last 2 months;
• had used an investigational drug within the last 30 days;
• had changed anti epileptic drug medication within the last 3 months;
• were likely to need vaccination e.g. for travel during the course of the trial
(except for influenza vaccine in patients with LAM);
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• were using strong inhibitors of CYP3A4 ( such as ketoconazole, voriconazole, 
itraconazole, tilithromycin or clarithromycin) or strong inducers (such as 
rifampicin or rifabutin);
* estimated from creatinine clearance calculated by the abbreviated MDRD study 
equation [281]:
GFR (mL per minute per 1.73 m2) = 186 X (SCr)-1.154 X (Age)-0.203 X 
(0.742 if female) X (1.210 if black)
** oestrogen containing contraceptives are not recommended in LAM. Acceptable 
contaceptive measures included prior hysterectomy, ovarectomy or tubal ligation, 
vasectomy, complete abstinance, barrier methods which included both a cervical 
diaphragm and spermicidal jelly and progesterone based contraceptives.
*** as measured on 24 hour protein collection
**** hyperlipidaemia was defined and managed according to clinical guidelines 
[282]. In participants, with unacceptably high lipid levels, these levels were reduced 
to recommended levels prior to initiation of sirolimus.
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5.5 Patient recruitment
Tuberous sclerosis patients were selected from individuals followed by the Medical 
Genetics Service for Wales, the Nephrology service at Zurich University Hospital and 
from participants in the UK National Registry of Renal Complications of Tuberous 
Sclerosis. Sporadic LAM patients were selected from the national cohort followed by 
The Respiratory Service at Nottingham University (The LAM Action Register). Patients 
followed at The Medical Genetics Service for Wales and the Zurich University Hospital 
were under the clinical care of one of the study doctors. The study doctor involved in 
their care selected potential participants and contacted them via mail. Participants in 
The National Registry of Renal Complications of TSC and The LAM Action Register 
already had given permission to be contacted about research studies. They were 
contacted by mail by one of the principal investigators. Potential participants received 
an information sheet (appendix 1) and a response sheet for return by prepaid post. Those 
that expressed a potential interest in participating were offered a face to face interview 
with one of the study doctors to provisionally assess eligibility, answer questions and 
obtain written consent prior to enrolment (appendix 2 -consent form).
5.6 Study design
After giving informed consent, patients had a baseline evaluation at a screening visit. 
This included a medical history and physical examination by one of the study doctors, 
cognitive function testing (see section 5.7), a renal MRI scan (see section 5.8), brain 
MRI scan (see section 5.8) , laboratory studies including renal profile, liver profile, 
bone profile, fasting lipids, fasing glucose, thyroid function, creatine phosphokinase 
(CPK), full blood count and differential, dipstick urine analysis, 24 hour urine protein 
clearance and spot urine protein-creatinine ratio. All female participants had a 
pregnancy test.
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Baseline chest X-ray and spirometry (FEV1 and FVC) was performed in all patients and 
high-resolution chest CT scan (see section 5.8) was performed in female patients where 
chest CT films from within the preceding twelve months were not available. Individuals 
with evidence of LAM had more extensive baseline pulmonary function tests consisting 
of FEV1, FVC and DLCO in a lung function laboratory. Patients who had epilepsy were 
given an epilepsy diary and instruction in its use. The current frequency and nature of 
seizures was recorded and the diary reviewed at each follow-up assessment. Mutation 
analysis was performed in participants with tuberous sclerosis in whom the genotype 
was unknown.
Patients were given a sheet with information regarding the use of other drugs when on 
sirolimus (appendix 3) and a contact number for where advice was available 24 hours a 
day (this was provided by the renal on call service at the Royal Sussex Hospital). 
Doctors involved in their care were given an information sheet regarding the trial and 
the investigational drug (appendix 4).
Patients received sirolimus orally once daily. Within two weeks of the baseline 
evaluation sirolimus was initiated at a dosage of 0.5 mg/m2/d. The start date of taking 
sirolimus was designated as day 1. Dosages were adjusted to achieve a trough level of 
3-6 nanograms per milliliter (ng/ml). Dose adjustments were calculated using the 
formula:
New sirolimus dose = current dose x (target concentration/current 
concentration)
Sirolimus levels were measured 7 days after a dosage increase.
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Follow-up evaluations were performed at 3 weeks, 2 months, 4 months, 6 months, 9 
months, 12 months, 18 months, and 24 months after initiation of sirolimus. Follow-up 
blood biochemistry and haematology studies (as baseline), pregnancy tests, dipstick 
urine analysis, spot urine protein:creatinine ratios and trough sirolimus levels were 
performed at each follow-up visit. Renal MRI scans were repeated after 2, 6, 12 and 24 
months on therapy.
Handheld spirometry (FEV1 and FVC) was carried out at each visit for patients with 
tuberous sclerosis alone. Patients with LAM (either sporadic or TSC associated) had 
handheld spirometry (FEV1 and FVC) at each visit apart from visits at baseline, 4 , 6 
and 12 and 24 months when FEV1, FVC and DLCO were measured in a lung function 
laboratory.
High resolution chest CT (subjects with LAM only -  sporadic or TSC related) was 
performed after 24 months on therapy to observe any effects on pulmonary disease. 
Brain MRI (TSC subjects only) was performed after 12 months on therapy to observe 
any effects on cortical tubers and subependymal nodules.
In between visits a study doctor telephoned participants to collect data regarding 
adverse events or changes in drug regimen. Calls occurred at 1 week, 1.5 months, 5 
months, 7.5 months 10.5 months, 15 months, 21 months and 25 months.
After two months, unless there had been a reduction in diameter from baseline of at 
least 10% in all measured AMLs, the dose of sirolimus was altered to achieve a trough 
serum level of 6-10 ng/ml unless unacceptable toxicity occurred. The total duration of
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treatment within the trial was 2 years unless the drug was stopped or temporarily 
withheld. The trough levels of sirolimus were selected in view of the trough level of 12- 
20 ng/ml recommended when sirolimus is used as a single agent immunosupressant in 
renal transplantation.
5.7 Cognitive function testing
Cognitive testing was carried out at baseline, 4 & 12 months by the same psychologist 
in a quiet and undisturbed testing environment. Only patients with English as their first 
language were evaluated for neurocognitive outcomes. IQ was determined for trial 
eligibility using the National Adult Reading Test [283]. Function was assessed in 3 
neurocognitive domains:
1) Recall memory was assessed using the List Learning, Story and Complex Figure 
measures of immediate and delayed verbal and spatial recall memory from the Adult 
Memory and Information Processing Battery (AMIPB) [284];
2) Recognition memory was assessed using the spatial recognition memory and pattern 
recognition memory subtests from the Cambridge Neuropsychological Test Automated 
Batteries (CANTAB) [285];
3) Executive skills were assessed using the self-ordered Spatial Working Memory task 
(SWM), the Stockings of Cambridge (SoC) planning task and the Intra-Dimensional 
Extra-Dimensional shifting task (IDED) from the CANTAB [285].
Parallel versions of tests were used to reduce practice effects.
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5.8 Imaging
Abdominal and brain imaging was performed by MRI using clinical 1.5-Tesla systems. 
Abdominal sequences comprised axial T2 Turbo Spin echo, T1 and T2 fat saturated 
with optional T1 coronal. Brain sequences comprised axial T2 weighted images, axial 
flair images and coronal 3D Spoiled Gradient Recalled. CT images of the lung were 
obtained during full inspiration, acquired with a low dose protocol, with a pitch of 
1.375:1 at 5 mm thickness, reformatted on lung algorithm to 5 mm and 1.25 mm.
Figure 4: A flow chart of evaluations in the trial
INFORMED CONSENT OBTAINED
i
SCREENING VISIT
within 2 
weeks
SIROLIMUS INITATED (dayl)
i
SIROLIMUS LEVEL AT 1 WEEK
i
FOLLOW UP EVALUATIONS AT:
3 WEEKS
2 MONTHS
4 MONTHS 
6 MONTHS 
9 MONTHS 
12 MONTHS 
18 MONTHS 
24 MONTHS
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Table 3: Data capture summary
Screen
ing
1
wk
3
wk
2
mth
4
mth
6
mth
9
mth
12
mth
18
mth
24
mth
History 
and exam ✓ ✓ * * ✓ * * ✓
Blood 
Tests (1) * * ✓ ✓ ✓ * *
Sirolimus
levels * ✓ ✓ ✓ ✓ ✓ ✓ * *
Pregnancy
test ✓ ✓ ✓ ✓ ✓ ✓ ✓ * ✓
Spot urine 
Protein: 
creatinine 
ratio
* * * * ✓ * *
24 hour
urine
protein
✓
Urine
Analysis * * ✓ ✓ * V* ✓ * ✓
Genotype
(2) ✓
Chest X- 
ray ✓
Spirometry ✓ * ✓ ✓ * ✓ ✓ ✓ *
Detailed
lung
function
tests
(3)
✓ * ✓ ✓ ✓
Cognitive
function
tests
✓ ✓ *
Renal MRI ✓ ✓ ✓ *
Brain MRI * *
(4)
CT thorax ✓
(5)
✓
(6)
Review of 
epilepsy ✓ ✓ <✓ ✓ ✓ ✓ * ✓ ✓
Telephone calls from a study doctor at 1 week, 1.5 months, 5 months, 7.5 months 
10.5 months, 15 months, 21 months and 25 months.__________________________
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Key to table
1 Renal profile, liver profile, bone profile, fasting lipids, glucose, thyroid 
function, CPK, full blood count and differential.
2 For participants with tuberous sclerosis in whom genotype is not already 
known.
3 Only in patients with LAM.
4 Only in patients with tuberous sclerosis
5 At baseline evaluation a high-resolution chest CT scan was performed in 
female patients where chest CT films from within the preceding twelve 
months were not available.
6 Patients with LAM only.
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5.9 Evaluation of response of angiomyolipoma
Response was assessed according to Response Evaluation Criteria in Solid Tumors 
(RECIST) which are summarised in table 4 [286]. At baseline, AMLs were categorized 
by size as measurable (greater than 20mm in longest diameter) or non-measurable. Up 
to five measurable AMLs, greater than 20 mm in longest diameter, were selected in 
each kidney and identified as target lesions. The longest diameter (LD) of each target 
lesion was recorded and the sum of the LD for all target lesions calculated. Non- 
measurable AMLs were recorded as non-target lesions. A complete response 
represented the disappearance of all lesions. A partial response represented at least a 
30% decrease in the sum of the LD of target lesions, using the baseline sum as the 
reference and stable non-target lesions. Progressive disease represented at least a 20% 
increase in the sum of the LD of target lesions (taking as a reference the smallest sum of 
the LDs recorded since the treatment started), progression of non-target lesions, or the 
appearance of 1 or more new lesions. Stable disease represented neither a partial 
response nor progressive disease. Patients with an overall complete or partial response 
were considered responders.
AML LDs were measured by a single radiologist (TD). Anonymized MRI scans were 
indentified by code numbers and the radiologist was not blind to the timing of the scans 
in relation to the study.
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Table 4: Response Criteria
* Complete Response (CR):
* Partial Response (PR):
* Progressive Disease (PD):
* Stable Disease (SD):
Evaluation of target lesions
Disappearance of all target lesions 
At least a 30% decrease in the sum of the LD of target 
lesions, taking as reference the baseline sum LD 
At least a 20% increase in the sum of the LD of target lesions, 
taking as reference the smallest sum LD recorded since the 
treatment started or the appearance of one or more new lesions 
Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum 
LD since the treatment started
Evaluation of non-target lesions
* Complete Response (CR): Disappearance of all non-target lesions
* Incomplete Response/ Persistence of one or more non-target lesion(s)
Stable Disease (SD):
* Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal
progression of existing non-target lesions
LD = largest diameter 
Overall response
Target lesions Non-Target lesions New lesions Ov
CR CR No CR
CR Incomplete response/SD No PR
PR Non-PD No PR
SD Non-PD No SD
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
5.10 Safety assessments
Safety assessments were based on reports of adverse events and the results of physical 
examination, laboratory determinations and other scheduled procedures. Adverse event 
reporting was done in accordance with the principles of Good Clinical Practice and the 
requirements of the Medicines for Human Use (Clinical Trials) Regulations 2004. 
Sample adverse event reporting cards are included in appendix 5.
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An adverse event (AE) was defined as any untoward medical occurrence in a patient 
which does not necessarily have a causal relationship with this treatment. An adverse 
reaction to an investigational medicinal product (AR) was defined as all untoward and 
un-intended responses to an investigational medicinal product related to any dose 
administered. All adverse events judged by either the reporting investigator or the chief 
investigator as having a reasonable causal relationship to a medicinal product qualified 
as adverse reactions.
All adverse events were evaluated for seriousness, causality and expectedness. Adverse 
events were graded according to the National Cancer Institute’s Common Terminology 
Criteria for Adverse Events v3.0 (CTCAE) [287]. A serious adverse event or serious 
adverse reaction was defined as any untoward medical occurrence or effect that at any 
dose fulfils at least one of the following criteria:
results in death; 
is life-threatening;
requires inpatient hospitalisation or prolongation of existing hospitalisation; 
results in persistent or significant disability/incapacity; or 
is a congenital anomaly/birth defect
The relationship of adverse events to the product being studied was determined 
according to the five categories classification below. Of the five, "possibly", "probably" 
and "definitely" related to an investigational medicinal product qualify as adverse 
reactions; "unlikely" and "not related" did not qualify as a reasonable causal 
relationship.
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Not related - temporal relationship of the onset of the event, relative to 
administration of the product, is not reasonable or another cause can by itself 
explain the occurrence of the event.
Unlikely -  temporal relationship of the onset of the event, relative to 
administration of the product, is reasonable but the event is more likely 
explained by another cause than by the product.
Possibly related - temporal relationship of the onset of the event, relative to 
administration of the product, is reasonable but the event could have been due to 
another, equally likely cause.
Probably related - temporal relationship of the onset of the event, relative to 
administration of the product, is reasonable and the event is more likely 
explained by the product than by another cause.
Definitely related - temporal relationship of the onset of the event, relative to 
administration of the product, is reasonable and there is no other cause to 
explain the event.
An unexpected adverse reaction was defined as an adverse reaction, the nature or 
severity of which is not consistent with the applicable product information i.e. the 
summary of product characteristics (SPC) or is not expected based on the knowledge of 
TSC and LAM. Expected advents based on knowledge of the natural history of TSC and 
LAM were defined as follows:
76
for TSC
Seizures; or
Haemorrhage from AML.
for LAM:
Pneumothorax;
Chest infection;
Chylothorax; or 
Haemoptysis;
Sirolimus-related treatment emergent adverse reactions were reported and were events 
not present at baseline or those present at baseline that worsened during treatment, and 
were definitely, probably or possibly related to sirolimus administration.
5.11 Toxicity and interruption or discontinuation of treatment
5.11.1 Hyperlipidaemia
Subjects developing significant hyperlipidaemia were given the option of having the 
sirolimus dose reduced or discontinued, or continuing on the protocol with concurrent 
therapy of their hyperlipidaemia. Management of hyperlipidaemia was based on clinical 
guidelines [288].These guidelines recommend that for secondary prevention treatment 
should be initiated in those with a risk threshold of > 20% cardiovascular disease risk 
over 10 years, calculated using the Joint British Societies chart. If resolution of 
hyperlipidaemia did not occur after 2 months of dietary therapy a lipid lowering agent,
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typically a statin, was initiated.
If cholesterol and/or triglyceride levels were not reduced to recommended levels with 
lipid lowering drugs, then the sirolimus dose would have been reduced by 50% until this 
has been achieved. Re-escalation of the sirolimus dose was permitted if the toxicity 
resolved.
5.11.2 Haematological toxicity
In the event of a significant hematological abnormality as outlined in the exclusion
criteria (i.e. Haematocrit < 30%, Neutrophil count < 1,500 mm^, total WBC < 3,000
mm3, platelets <100,000 mm^) sirolimus was discontinued until resolution of the 
abnormality. Sirolimus was then restarted at 50% of the previous dose. Re-escalation of 
the sirolimus dose was permitted.
5.11.3 Seizure control
Sirolimus would have been stopped if seizure control deteriorated.
5.11.4 Pulmonary toxicity
If minor but unambiguous pulmonary infiltrates were found on a PA chest film, the 
investigator would have either held the drug or reduced the dose of sirolimus by 50%. If 
the infiltrates did not steadily resolve, or if grade 3 or greater pulmonary toxicities 
occurred at any time, the drug would have be withheld until symptomatic and 
radiographic resolution occurred, and then the sirolimus dose restarted at 50% of the 
prior dose. Re-escalation of sirolimus was permitted if the toxicity resolved.
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5.11.5 Infectious toxicities
If grade 2 infectious complications occurred, and antibiotics that interfere with the 
metabolism of sirolimus were prescribed, appropriate dose adjustments were made or 
sirolimus withheld for the duration of the antibiotic treatment. Sirolimus was withheld 
for all grade 3 or greater infectious complications until infection was resolved. Re­
escalation of the sirolimus was permitted if the toxicity resolved.
5.11.6 Mucositis/stomatitis
If grade 2 symptoms occured, the sirolimus dose was decreased by 50% or withheld for 
at least 2 weeks. Sirolimus was withheld if grade 3 or greater toxicities occurred and 
restarted at 50% of the prior dose. Re-escalation of the sirolimus was permitted if the 
toxicity resolved
5.11.7 Other toxicities
For grade 1 or 2 sirolimus-associated toxicity the dose of sirolimus could be maintained, 
reduced, withheld or increased at the study doctors’ discretion. If a subject experienced 
sirolimus associated grade 3 or 4 toxicity, or persistent grade 2 toxicity unresponsive to 
treatment, the drug could be held until toxicity regressed to grade < 1 or to the baseline 
from screening. The study drug could then be resumed at the previous dose. A dose 
decrease of 20-50% was permitted at the discretion of the investigator. Subsequent re­
escalation of dose was also permitted if toxicity did not recur. If a subject experienced 
recurrent sirolimus-related grade 3/4 toxicity or persistent grade 2 toxicity unresponsive 
to treatment, despite a 50% dose reduction the sirolimus would have been withheld for 
the rest of the trial.
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5.11.8 Discontinuation depending on response
Consideration would have been given for participants with tuberous sclerosis to dose 
reduction or discontinuation of sirolimus should the LDs of all measured 
angiomyolipomas be reduced by at least 75% from their original size. Sirolimus would 
also have been discontinued if there had been no decrease in size from the baseline 
documented on serial MRI scans after 4 months of the highest sirolimus dose. However 
in sporadic LAM patients it was to be continued for the full two years.
5.11.9 Dosage reduction due to high serum levels
Trough serum levels above 10 ng/ml resulted in dosage reduction. Dose reduction 
was done according to trough levels as follows;
Trough level
10.1-15 ng/ml- withhold dose for 24 hours then resume at 50% of 
previous dose
15.1-24 ng/ml- withhold dose for 48 hours then resume at 25% of 
previous dose
over 24.1 ng/ml- withhold dose for 72 hours then resume at 10% of 
previous dose
5.12 Statistics
5.12.1 Sample size
The sample size calculation was based on a Fleming single stage design setting pi at 
0.1, p2 at 0.4, a at 0.05 and p at 0.1 (where pi is the response rate below which the 
treatment would not be considered for further study, p2 the response rate above which 
the treatment would certainly be considered for further study, a the probability of 
concluding that the response rate is greater than p i when that is false and p the
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probability of concluding that the response rate is less than p2 when that is false). A 
Fleming single stage design was chosen in view of the restricted numbers of potentially 
eligible participants. We required 14 patients and recruited 16 to allow for drop out.
5.12.2 Statistical analysis of primary endpoint
The primary efficacy end point of this study was objective renal angiomyolipomas 
response rate (the percentage of patients with CR or PR). The primary efficacy analysis 
was based on the intention-to-treat population. The per protocol population was defined 
as all those participants in the study excluding those who had not complied with the 
protocol sufficiently that they were likely to show the effects of the treatment. Those 
who had failed to comply sufficiently were defined as those who did not receive at least 
four months at 6-10 ng/ml unless they achieved a response.
We also determined the number and percentage of those participants who were 
considered responders at the time of the 24 month MRI scan and those in whom the 
drug was discontinued because of a 75% reduction from the baseline LDs of all 
measured angiomyolipomas combined.
5.12.3 Statistical analysis of lung function
The lung function data is expressed as percentage of predicted values to allow for 
change over time. The annual rate of change in FEV1, FVC and DLCO was determined 
by linear regression.
5.12.4 Statistical analysis of cognitive function
Test scores were converted to percentile band scores (below 5th, 5th-9th, 10th-24th, 25th- 
49th, 50th-74th, 74^-89^ or 90th and above) according to published UK population norms
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for age, and sex for each test version. This enabled comparison across parallel forms of 
tasks. We calculated summary scores across tasks30 by allocating an integer score to 
each centile band (below 5th = 1, 5lh-9,h = 2, 10,h-24lh = 3, 25,h-49,h = 4, 50th-74th = 5, 
75<h-89lh = 6, 90th and above = 7) and adding the integer scores across the tests in each 
domain of neurocognitive function. The total immediate recall memory score was the 
sum of the integer scores for list learning, story recall and figure recall; the total 
immediate recognition memory score was the sum of the pattern recognition and spatial 
recognition integer scores and the total executive score was the sum of the SWM, SoC 
and IDED integer scores.
5.13 Results
5.13.1 Characteristics of the patients
A total of 16 patients, 13 female and 3 male, were enrolled from October 2005 to 
September 2007. Six patients had sporadic LAM, 10 had tuberous sclerosis; of whom 3 
also had tuberous sclerosis related LAM. Three patients had undergone an unilateral 
nephrectomy. Of the 13 patients with both kidneys remaining the target lesions were 
unilateral in 7 patients (6 with LAM and 1 with tuberous sclerosis) and bilateral in 6 
patient (all with tuberous sclerosis). The median number of designated target lesions 
was 3 (range 1-9). Four patients had epilepsy which was well controlled with 
antiepileptic medication.
During the trial one patient with sporadic LAM died from a respiratory infection. One 
patient withdrew for lung transplantation, two withdrew for personal reasons unrelated 
to the study, one withdrew because of sirolimus related peripheral oedema and one 
patient for elective surgery for AML. Additionally, sirolimus was permanently
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discontinued in one patient due to fatigue and in another due persistent proteinuria. 
The genotypes of the patients with tuberous sclerosis are shown in table 5.
Table 5: The genotypes of the patients with tuberous sclerosis
Patient Result
TSC1(L)
TSC2(L) TSC2 c.5227_5244 del 18bp
no mutation found (*)
no mutation found
TSC2 c .llllC > T
TSC2 c.4947C>G
TSC2 deletion exon 7-19 (somatic mosaic)
no mutation found
mutation analysis not done
mutation analysis not done
no mutation found
TSC3
TSC4
TSC5
TSC6
TSC7
TSC8(L)
TSC9
TSC10
TSC1 and TSC2 mutation screening was performed using denaturing high-performance 
liquid chromatography. PCR products were on an ABI 3100 Genetic Analyser. 
Multiplex ligation-dependent probe amplification (MLPA) was performed on TSC2 
using a standard kit, P046-B2 (MRC Holland, Amsterdam, the Netherlands).
(* MLPA not performed to date)
Ten patients completed the 24 month trial (Figure 5). At 2 months 15 patients 
underwent renal MRI evaluation, one patient fractured her tibia and fibular shortly prior 
to the 2 month assessment. Thirteen patients underwent renal MRI evaluation at 6 
months, 2 patients had withdrawn from the study at this point and one had a respiratory 
infection and was unable to attend for the scan. At 12 months, 12 patients underwent 
renal MRI evaluations four patients having withdrawn. At 24 months 10 underwent 
renal MRI evaluation as 5 had withdrawn and one patient had died.
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Pulmonary function data for patients with LAM (tuberous sclerosis related or sporadic) 
was available for 9 patients at baseline, for 8 at 4 months, for 6 at 6 months, for 7 
patients at 12 months and for 5 patients at 24 months.
Cognitive function data was available for 14 patients at baseline and at four months and 
for 11 patients at 12 months, including 7 with tuberous sclerosis.
At 2 months 7 patients achieved a decrease greater than 10% in all measured AMLs, six 
were maintained at the 3-6 ng/ml range and one (LAM2) increased to 6-10ng/ml 
(originally this was done in error but was well tolerated and continued at this level 
following discussion with the patient). A decrease greater than 10% in all measured 
AMLs at 2 months was not achieved in 8 patients. Of these 5 were maintained at the 3-6 
ng/ml range, 3 because of toxicity and 2 because of patient preference and 3 were 
escalated to the 6-10 ng range. In the patient who did not have a 2 month renal MRI 
because of a fractured tibia and fibula the sirolimus was discontinued until after the 
fracture healed and was not escalated above 3-6 ng/ml. Sirolimus was not discontinued 
on the basis of responses in any patients as no reduction of 75% or greater was seen 
from the baseline LDs of measured AMLs in any patients.
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Figure 5. Flow diagram summarising patients and assessments.
3 were not enrolled
2 were ineligible 
1 declined to participate
14 had neurocognitive 
assessment at baseline
19 patients with tuberous sclerosis 
or sporadic
lymphangioleio myomatosis 
(LAM) screened
±
16 patients enrolled
6 had LAM only
3 had tuberous sclerosis and LAM
7 had tuberous sclerosis only
16 had angiomyolipomas 
measured at baseline
9 with LAM had 
pulmonary function 
assessed at baseline
1 withdrew
1 withdrew
13 had neurocognitive 
assessment at 4 months
1 withdrew *------
1 withdrew
11 had neurocognitive 
assessment at 12 months
1 withdrew 
1 died
SIROLIMUS THERAPY, 16 started
15 had angiomyolipomas 
measured at 2 months*
13 had angiomyolipomas 
measured at 6 months*
12 had angiomyolipomas 
measured at 12 months
10 had angiomyolipomas 
measured at 24 months
8 had pulmonary function 
assessed at 4 months
6 had pulmonary function 
assessed at 6 months*
6 had pulmonary function 
assessed at 12 months*
5 had pulmonary function 
assessed at 24 months
* One patient who was still in the study was unable to undergo magnetic resonance 
imaging of the kidneys at the 2-month assessment and another at the 6-month 
assessment because o f inter-current illness. # One patient was unable to undergo 
pulmonary function tests at 6 and at 12 months because o f inter-current illness.
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5.13.2 Response of AMLs
The data on treatment response is illustrated in table 6 and figure 6. Figure 7 shows 
MRI findings in patient TSC5 at baseline and at 24 months. A response at any time 
during the study period was seen in 8 of 16 patients (50%). No patients achieved a 
complete response and 8 (50%) achieved a partial response, 4 of 10 with tuberous 
sclerosis and 4 of 6 with sporadic lymphangioleiomyomatosis. One new non-target 
lesion was seen in one patient with sporadic lymphangioleiomyomatosis at the 12 
month renal MRI but this was no longer seen at the 24 months. In all other participants 
at all other time points the responses of non-target lesions were evaluated as incomplete 
responses/ stable disease.
In the per protocol group of 10 patients the response rate was 80%. All the responses 
that occurred were seen in the per protocol group.
Of the 10 participants who were evaluated at 24 months a response was seen in 4 (40%), 
at that time point, i.e. 25% of the original 16 participants. Of the other 6 evaluated at 24 
months, one patient achieved a response at 2 months but there was a subsequent 
increase in the sum LD sufficient to be designated progressive disease although the sum 
LD remained below baseline and the other 5 had stable disease. Of the 6 participants 
who were not evaluated at 24 months 1(17%) had achieved a response during their 
participation in the study. Of the 11 participants who were evaluated by 24 month MRI 
scan or were deceased by this time point, 4 (36.3%) were classified as being responders 
at that time point.
Of the 12 participants maintained at 3-6ng/ml at 2 months 5 (42%) achieved a response
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at any time during the study period. Of the 6 maintained at that level because of a 10% 
or greater decrease in size of measured AMLs at 2 months, 4 (67%) achieved a response 
at any time during the study period. Of the 5 maintained at 3-6ng/ml or less at 2 months 
because of toxicity or patient preference one (20%) achieved a response at any time 
during the study period although only 3 of these patients were evaluable at 24 months. 
Of the 7 patients who were maintained on 3-6 ng/ml or lower who were evaluated at 24 
months one (14.3%) was considered a responder at the time of the 24 month evaluation 
which is 6.3% of the initial 16 participants.
Of the 4 patients escalated to 6-10 ng/ml at 2 months, 3 (75%) achieved a response and 
one withdrew. Three of these patients had not achieved a 10% or greater decrease in 
size of measured AMLs at 2 month but of these 3 patients 2 achieved a response during 
the trial.
Of the 48 individual target lesions evaluated, 41 (85%) were smaller at the last 
measurement made than at baseline, 2 were the same size and 5 were larger, including 4 
from one patient (table 7). A decrease in LD at at least one time point was seen in 44 
(92%) lesions. At least one target lesion exhibited a decrease in LD from baseline in 
each patient. Three target lesions (all in the same patient) showed no decrease in LD but 
rather a continued increase in size over the duration of the study. Nine target lesions 
showed a decrease in sum LD followed by an increase back towards or above baseline 
LD at the last evaluation available. Of 23 target lesions evaluated at 24 months, 21 
showed a decrease in LD compared with baseline, 2 lesions had the same LD as 
baseline.
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Figure 6: Changes in angiomyolipoma burden during sirolimus therapy.
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Renal angiomyolipomas were measured at baseline and at 2,6,12 and 24 months by 
magnetic resonance imaging. The sum o f the longest diameters o f all target 
angiomyolipomas in each patient was calculated at each time point and the percentage 
reduction calculated by comparison to the baseline value. Each solid line shows change
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in angiomyolipoma burden in one patient. The upper dashed line represents the 
baseline value and the lower dashed line 70% o f the baseline value. Patients in whom 
the sum o f the longest diameters o f target angiomolipomas fell below 70% of the 
baseline value are defined as partial responders by the RECIST criteria.
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Table 6: Response of angiomyolipomas to sirolimus.
Percent Reduction in Sum of Longest Diameters of Angiomyolipomas
2 months 6 months 12 months 24 months
LAM1 10 ND 13 Deceased
LAM2 6 31 42 50
LAM3 14 14 14 41
LAM4 8 8 23 38
LAM5 4 Withdrew
LAM6 37 Withdrew
TSC1 (L) 28 28 30 28
TSC2 (L) 13 27 27 Withdrew
TSC3 9 14 Withdrew
TSC4 2 2 Withdrew
TSC5 16 32 32 33
TSC6 ND 5 29 26
TSC7 22 23 30 28
TSC8 (L) 34 24 18 17
TSC9 16 11 18 21
TSC10 2 6 14 17
Response is expressed as percentage reduction in the sum of the longest diameters of 
target angiomyolipomas in each patient measured by magnetic resonance imaging 
(MRI) compared to baseline. Reductions o f 30% o f more are categorised as partial 
responses by the RECIST criteria and are highlighted in red. 8 o f 16 patients (50%) 
achieved a partial response. (ND = MRI not done due to inter-currrent illness).
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Table 7: Change in longest diameters of individual target angiomyolipomas.
Patient Angiomyolipoma baseline 2 Months 6 Months 12 Months 24 Months
LAM1 R1 2.2 1.4 ND 2.0 Deceased
R2 2.6 2.7 ND 2.3 Deceased
R3 2.3 2.3 ND 1.9 Deceased
LAM2 R1 2.8 2.5 1.4 1.2 1
R2 2.0 2.0 1.9 1.6 1.4
LAM3 R1 2.2 1.9 1.9 1.9 1.3
LAM4 LI 2.8 2.5 2.8 2.4 2.2
L2 2.0 1.9 1.6 1.3 0.8
LAM 5 R1 2.3 2.2 Withdrew
LAM6 LI 5.6 3.4 Withdrew
L2 2.7 1.7 Withdrew
L3 2.6 1.8 Withdrew
TSC1(L) R1 2.4 1.9 1.9 1.9 2.0
R2 2.2 1.4 1.4 1.3 1.3
TSC2(L) R1 3.2 2.6 2.1 2.3 Withdrew
R2 2.2 1.8 1.4 1.6 Withdrew
R3 2.2 2.1 2.0 2.0 Withdrew
LI 3.8 3.4 2.8 2.4 Withdrew
TSC3 R1 2.4 2.2 2.1 Withdrew
R2 2.4 1.9 1.9 Withdrew
LI 5.4 4.6 4.3 Withdrew
L2 2.2 2.4 1.9 Withdrew
L3 2.7 2.6 2.8 Withdrew
TSC4 R1 14.1 12.8 13.3 Withdrew
R2 2.7 2.7 2.5 Withdrew
R3 3.4 3.3 3.7 Withdrew
R4 3.2 4.2 4.2 Withdrew
R5 5.4 5.4 6.4 Withdrew
LI 10.6 10.2 8.3 Withdrew
L2 4.4 4.5 4.8 Withdrew
L3 3.6 3.5 3.4 Withdrew
L4 3.4 3.3 3.2 Withdrew
TSC5 R1 2.3 1.9 1.8 1.8 1.6
R2 4.5 3.8 2.8 2.8 2.9
TSC6 R1 2.4 ND 2.3 1.8 1.6
LI 2.8 ND 2.3 1.7 2.1
L2 2.4 ND 2.6 1.9 1.9
TSC7 R1 2.5 2.4 2.2 1.8 1.8
R2 3.8 2.8 2.7 2.8 3.2
R3 3.3 2.4 2.3 2.1 2.1
R4 2.9 2.2 2.4 2.1 1.9
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TSC8(L) R1 3.9 2.3 2.6 2.5 2.5
LI 4.3 3.1 3.6 4.2 4.3
TSC9 R1 2.0 1.7 1.7 1.9 1.7
R2 4.2 3.5 3.8 3.2 3.2
TSC 10 R1 2.9 2.8 2.8 2.2 2.0
LI 3.2 2.9 2.7 2.5 2.5
L2 3.3 3.5 3.3 3.4 3.3
Target angiomyolipomas in the right (R) and/or left (L) kidney in each patient were 
visualised by magnetic resonance imaging (MRI) at baseline and at 2,6,12 and 24 
months and the longest diameter o f each angiomyolipoma was measured. Values are
cm. ND = MRI not done due to inter-current illness.
Figure 7: MRI scans showing AMLs in the abdomen of a patient (TSC5) with the 
tuberous sclerosis.
Baseline
24 months
Unilateral AMLs in a patient with a single kidney are shown at baseline and after 24 
months of sirolimus therapy. A lesion in the right kidney is identified by an arrow.
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5.13.3 Pulmonary function
Baseline lung function in patients with lymphangioleiomyomatosis showed wide 
variation in airflow obstruction and gas transfer (fig. 8 and table 8). FEV1 and FVC fell 
in most patients during the trial. The mean +/-SD decline in FEVi and FVC were 76 +/- 
52 and 55 +/-94 ml/yr respectively for the 5 patients with measurements over 2 years 
and for the 7 patients with at least one year of measurements 49 +/-93 and 100 +/-181 
ml/yr respectively. Mean changes in DLCO for the 5 patients completing 2 years and 
for the 6 completing at least one year were -0.49 +/- 0.55 and -0.04 +/-1.23 
ml/min/mmHg/yr.
Four patients (LAM1, LAM2, LAM4 and TSC1) had serial measurements of FEVI 
prior to enrollment, for 16, 132, 42 and 106 months respectively. Mean annual change 
in FEVI for these patients before and during the trial were -172 and -94, -122 and -89, 
-90 and +10 and -49 and -69 ml/yr respectively. There were no clinically relevant 
changes in lung CT appearances during the trial.
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Figure 8: Pulmonary function studies in patients with sporadic or tuberous
sclerosis-associated lymphangioleiomyomatosis
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Forced expiratory volume at 1 second (FEVI), forced vital capacity (FVC) and 
diffusing capacity o f the lung for carbon monoxide (DLC0) are shown as percentages o f 
the predicted value for women o f equivalent age and height.
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Table 8: Pulmonary function tests in patients with tuberous sclerosis-associated or
sporadic lymphangioleiomyomatosis.
FEV!
% pred. Litres Annual rate of 
change, ml/yr
Patient Baseline Baseline 4 Mo 6 Mo 12 Mo 24 Mo
LAM1 20 0.41 0.50 not done 0.34 died -94
LAM2 41 1.11 1.20 1.15 0.98 1.00 -89
LAM3 40 1.03 0.91 0.80 0.99 0.71 -120
LAM4 52 1.50 1.53 1.59 1.49 1.55 +9
LAM5 85 2.55 withdrew
LAM6 23 0.63 0.55 withdrew -240
TSC1(L) 66 2.29 2.32 2.28 2.46 2.13 -69
TSC2(L) 93 2.43 2.45 2.53 2.56 withdrew +138
TSC8(L) 92 2.69 2.57 2.53 2.47 2.43 -114
FVC
% pred Litres Annual rate of 
change, ml/yr
LAM1 42 1.01 1.02 not done 0.58 died -463
LAM2 101 3.19 3.20 3.02 2.94 3.05 -78
LAM 3 98 2.96 2.94 2.81 3.02 2.52 -198
LAM4 80 2.65 2.83 3.03 3.00 2.83 +52
LAM5 92 3.18 withdrew
LAM6 53 1.71 1.42 withdrew -870
TSC1(L) 102 4.10 4.35 4.24 4.41 4.16 0
TSC2(L) 98 3.01 3.14 3.17 3.06 withdrew +34
TSC8(L) 119 4.01 3.94 3.77 3.89 3.86 -49
DLco
% pred ml/min/mmHg Annual rate of 
change
ml/ mi n/mmHg/y r
LAM1 10 2.12 3.25 not done not done died +3.39
LAM2 54 13.43 12.33 12.1 12.70 12.03 -0.44
LAM3 37 8.87 8.81 8.54 8.84 8.21 -0.29
LAM4 69 17.70 16.12 13.77 17.02 15.05 -0.70
LAM5 47 12.42 withdrew
LAM6 24 5.94 4.96 withdrew -2.94
TSC1(L) 40 11.97 13.25 14.32 15.52 12.68 +0.22
TSC2(L) 77 18.75 17.98 17.8 20.83 withdrew +2.27
TSC8(L) 70 18.10 24.55 24.84 23.83 18.22 -1.28
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5.13.4 Neurocognitive function
The mean (+/-SD) IQ of patients with tuberous sclerosis was 107 (+/-12) and of 
sporadic lymphangioleiomyomatosis patients 105 (+/-15). Patients with tuberous 
sclerosis showed neurocognitive deficits (performance <5th percentile) in 9 of 88 tests 
(10.2%) at baseline, in 6 of 88 (6.8%) at 4 months and in 7 of 77 (9.1%) at 12 months 
(table 9). By comparison, patients with sporadic lymphangioleiomyomatosis showed 
deficits in 2 of 63 tests (3.2%) at baseline, 1 of 45 (2.2%) at 4 months and none of 44 
at 12 months. Most deficits were in executive function. All patients showed changes 
in test performance during the trial. Six patients (TSC1, TSC 5, TSC7, TSC8, LAM1 
and LAM4) had greater than one percentile band decrease at 12 months compared to 
baseline in at least one test.
Seven patients with tuberous sclerosis completed neurocognitive assessment at 12 
months and 1 (TSC4) withdrew after the 4 month assessment. Seven of the 8 showed 
an increase in recall memory scores from baseline. In contrast, recognition memory 
scores fell in 5 of 8 and none showed an increase. Executive scores increased in 5 of 8 
patients (figure 9).
Of the 5 patients with sporadic lymphangioleiomyomatosis, 4 completed 12 month 
assessments and one (LAM5) withdrew after the 4 month assessment. Three showed 
increases in recall memory scores, two increased recognition memory scores and 4 
increased executive scores (Figure 9).
One patient with tuberous sclerosis and 2 with sporadic lymphangioleiomyomatosis 
showed decreased recall memory scores. These patients (TSC3; LAM3; LAM6) had
97
the highest baseline scores. No patient showed an increase across all three domains 
and none a decrease across all three domains (figure 9).
Table 9: Neurocognitive Tests Percentile Scores
TESTS TSC1
TSC
2
TSC
3
TSC
4
TSC
5
TSC
6
TSC
7
TSC
8
LA
Ml
LA
M2
LA
M3
LA
M4
LA
M5
LA
M6
AMIPB
List
learning
Immediate
recall
B 90 <5 50 25 50 75 25 75 75 25 25 75 75 75
4 90 <5 50 90 25 90 50 75 90 25 50 75 — 75
12 90 <5 50 — 75 90 50 75 90 50 50 90 — —
List
learning
Delayed one 
list
Recall
B 90 6 75 25 50 90 25 50 — 10 50 90 50 75
4 75 6 50 90 50 90 75 50 90 10 50 75 — 75
12 90 10 50 — 50 90 50 75 90 50 50 90 — —
Complex
figure
Immediate
recall
B 50 10 90 25 50 75 6 90 50 10 50 50 25 75
4 90 50 75 50 75 50 50 75 90 25 75 25 — 90
12 90 50 90 — 90 50 50 50 50 10 50 25 — —
Complex
figure
Delayed
recall
B 75 25 90 25 75 75 10 90 — 10 50 50 50 75
4 90 25 90 50 75 25 50 90 90 25 75 25 — 90
12 90 50 90 90 50 25 75 25 25 50 25 — —
Story
Immediate
recall
B 50 10 50 50 75 50 50 90 90 50 10 90 90 25
4 90 25 50 90 25 50 90 50 90 50 25 25 — 90
12 75 25 75 _ _ _ 25 75 75 90 90 90 50 25 — —
Story
Delayed
recall
B 75 25 50 90 75 25 50 90 90 50 6 90 90 25
4 90 10 75 90 10 75 90 75 90 75 25 25 — 90
12 50 25 75 25 90 50 90 90 90 75 25 — —
CANTAB
SWM
>4 betwn 
errors
B 10 <5 75 10 25 10 <5 50 50 10 10 75 10 50
4 10 <5 90 10 25 10 6 50 90 25 25 50 — 50
12 50 <5 90 — 10 10 <5 25 10 50 90 90 — —
soc
Trials in 
min moves
B 75 <5 25 50 <5 25 25 25 25 50 25 25 10 <5
4 90 <5 75 25 50 50 <5 50 50 90 25 75 — 25
12 50 10 90 — <5 25 <5 75 25 90 25 75 — —
IDED
Errors over B 6 50 50 10 25 <5 <5 <5 25 25 <5 <5 50 50
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TESTS TSC1
TSC
2
TSC
3
TSC
4
TSC
5
TSC
6
TSC
7
TSC
8
LA
Ml
LA
M2
LA
M3
LA
M4
LA
M5
LA
M6
stages 1-7 4 10 75 50 25 50 <5 10 75 25 25 6 75 — <5
12 10 50 50 — 10 25 25 75 25 75 6 25 — —
PRM
Percent B 90 10 50 50 75 75 25 50 90 10 25 90 50 90
correct 4 90 10 25 25 90 75 25 10 90 10 25 25 — 90
12 90 10 10 — 75 75 25 25 90 6 50 50 — —
SRM
Percent B 25 <5 25 75 25 75 6 50 25 25 10 50 — 25
correct 4 25 <5 25 25 50 25 6 25 10 6 10 25 — 25
12 25 <5 25 — 6 50 6 <5 50 10 10 50 — —
Numbers refer to the following percentile bands:
<5 = “Below the 5th percentile 
6 = “Above 5th but below the 10thpercentile”
10 = “Between 10th and24thpercentiles”
25 = “Between 25th and 49th percentiles ”
50 -  “Between 50th and 74th percentiles ”
75 = “Between 75th and 89th percentiles ”
90 = “In or above the 90th percentile ”
Key: AMIPB = Adult Memory and Information Processing Battery; CANTAB = 
Cambridge Neuropsychological Testing Automated Battery; SWM = Spatial Working 
Memory subtest; >4 betwn errors = between errors on 4 or more boxes; SOC = 
Stockings o f Cambridge subtest; Trials in min moves = Trials in minimum moves; IDED 
= Intra-Dimensional Extra-Dimensional subtest; PRM  = Pattern Recognition Memory 
subtest; SRM = Spatial Recognition Memory subtest. B = Baseline testing session; 4 =
4 months testing session; 12 = 12 months testing session.
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Figure 9: Neurocognitive test percentile scores.
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Test performance was measured at baseline and at 12 months (at 4 months in patients 
TSC4 and LAM6 who withdrew prior to the 12 month assessment) using parallel test
versions.
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5.13.5 Neuroimaging
Baseline cranial MRI scans in patients with tuberous sclerosis showed cortical tubers 
and sub ependymal nodules but no subependymal giant cell astrocytomas and no 
changes were seen at 12 months.
5.13.6 Safety
The most common adverse events were mouth ulcers, upper respiratory tract 
infection/bronchitis and proteinuria (table 10). Seven serious adverse events occurred. 
One patient with sporadic LAM died following a respiratory infection. Another two 
LAM patient were admitted to hospital, one with pharyngitis and the other with a chest 
infection. The four remaining serious adverse events were thought to be unlikely or 
definitely not related to sirolimus: a fracture of the tibula/fibula after a fall, chest pain 
for which no cause was found, urinary obstruction secondary to an ovarian cyst and 
musculoskeletal back pain. No patient had a seizure during the study period. Upper 
respiratory tract infections were more common in patients with LAM, metabolic 
toxicities were more common in patients with tuberous sclerosis.
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Table 10: Sirolimus-related treatment -emergent adverse events
C a t e g o r y Diagnosis No. of 
events
No. of 
patients
Grade
1-2
Grade
3-4
Grade
5
Gastrointestinal
Oral mucositis All 9 9 9 - -
SLAM 4 3 4 - -
TLAM 3 2 3 - -
TSC 2 1 2 - -
Diarrhoea All 1 1 1 - -
SLAM 1 1 1 - -
TLAM - - - - -
TSC - - - - -
Nausea All 1 1 1 - -
SLAM 1 1 1 - -
TLAM - - - - -
TSC - - - -
Infection
Upper respiratory tract or bronchitis All 16 5 15 - 1
SLAM 16 5 5 - 1
TLAM - - - - -
TSC - - - - -
Pharyngitis All 1 1 - 1 -
SLAM 1 1 - 1 -
TLAM - - - - -
TSC - - - - -
Urinary tract infection All 3 3 3 - -
SLAM 2 2 2 - -
TLAM 1 1 1 - -
TSC - - - - -
Cellulitis All 2 2 2
SLAM - - - - -
TLAM 1 1 1 - -
TSC 1 1 1 - -
Oral cavity All 1 1 1 - -
SLAM 1 1 1 - -
TLAM - - - - -
TSC - - - - -
Metabolic
Proteinuria All 5 5 5 - -
SLAM - -
TLAM 1 1 1 - -
TSC 4 4 4 - -
Raised creatinine kinase All 3 3 3 - -
SLAM - -
TLAM 2 2 2 - -
TSC 1 1 1 - -
Hypertriglyceridaemia All 2 2 2 - -
SLAM - - - - -
TLAM 1 1 1 - -
TSC 1 1 1 - -
Raised ALP All 1 1 1 - -
SLAM - - - - -
TLAM - - - - -
TSC 1 1 1 - -
Hypokalaemia All 1 1 1 - -
SLAM 1 1 1 - -
TLAM - - - - -
TSC - - - - -
Soft tissues
Peripheral oedema All 3 3 3 - -
SLAM - - - - -
TLAM 1 1 1 - -
TSC 2 2 2 - -
- -
- -
- -
- -
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C a t e g o r y Diagnosis No. of 
events
No. of 
patients
Grade
1-2
Grade
3-4
Grade
5
Constitutional symptoms
General malaise All 1 1 1 - -
SLAM 1 1 1 - -
TLAM - - - - -
TSC - - - - -
Fatigue All 3 3 3 - -
SLAM - - - - -
TLAM 2 2 2 - -
TSC 1 1 1 - -
Dermatolgy
Acneform rash All 2 2 2 - -
SLAM - - - - -
TLAM - - - - -
TSC 2 2 2 - -
Exacerbation of eczema All 1 1 1 - -
SLAM - - - - -
TLAM 1 1 1 - -
TSC - - - - -
Cardiac
Palpitations All 2 2 2 - -
SLAM 2 2 2 - -
TLAM - - - - -
TSC - - - - -
Neurology
Depression All 1 1 1 - -
SLAM - -
TLAM - -
TSC 1 1 1 - -
Endocrine
Hypothyroidism All 1 1 1 - -
SLAM - -
TLAM - -
TSC 1 1 1 - -
Ocular
Retinal tear All 1 1 1 - -
SLAM - -
TLAM 1 1 1 - -
TSC - -
Blood
Anaemia All 1 1 1 - -
SLAM - -
TLAM - -
TSC 1 1 1 - -
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5.14 Discussion
5.14.1 Summary
This trial determined the response of renal angiomyolipomas in patients with tuberous 
sclerosis or sporadic lymphangioleiomyomatosis to 2 years of sirolimus treatment. A 
response (as defined by the RECIST criteria) was achieved in 8 out of 16 (50%) patients 
overall and in 8 of 10 (80%) in the per protocol group. The reduction in sum LD was 
sustained over the 2 year duration of sirolimus treatment for the majority of patients. A 
response was seen in 42% of patients maintained at a sirolimus dose of 3-6 mg/ml. Of 
23 angiomyolipomas evaluated at 24 months, 21 were smaller and 2 were unchanged.
One previous trial reported by Bissler et al. investigated sirolimus treatment for 
angiomyolipoma in patients with tuberous sclerosis or sporadic 
lymphangioleiomyomatosis and found a mean reduction in angiomyolipoma volume of 
47% at 12 months [279]. In the current trial angiomyolipomas measured at 12 months 
showed a mean reduction in their longest diameters of 25% compared to baseline, 
equivalent to a volume reduction of 60% if a spherical shape is assumed.
While 12 of 16 patients in the current trial were maintained at trough blood levels of 3-6 
ng/ml and the other 4 at 6-10 ng/ml all but one of the patients in the trial by Bissler et 
al. were escalated to trough blood levels of 10-15 ng/ml. The current trial shows that 
sirolimus levels at the lower end of the immunosuppressive range are effective in 
reducing angiomyolipoma size in tuberous sclerosis or sporadic 
lymphangioleiomyomatosis.
In the trial of Bissler et a l  angiomyolipoma volumes increased after sirolimus therapy 
was withdrawn at 12 months, returning to 85.9% of the baseline value by 24 months. 
Our study suggests that AML regression is maintained or increased during the second
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year of sirolimus therapy. Longer term therapy might need to be considered in patients 
with tuberous sclerosis or lymphangioleiomyomatosis.
In the 10 patients with LAM there was no sustained improvement in lung function, nor 
was there any apparent change on chest imaging. In recent studies of 
lymphangioleiomyomatosis, the mean rate of decline in FEVi has ranged from 75-118 
ml/yr [32, 41]while in this trial it was 76 ml/yr in 5 patients who had measurements over 
2 years and 49 ml/yr in 7 patients with measurements over one year or more. Our 
findings in four patients with serial measurements prior to as well as during treatment 
were compatible with sirolimus causing some slowing in the rate of decline in FEVI. 
We did not observe the improvement in FEV1 and FVC seen by Bissler et al. although 
in both studies there was no sustained improvement in DLCO. This difference between 
studies may reflect differences in sirolimus levels achieved or in the baseline lung 
function of the patients or may be a reflection of the small patient numbers in both 
studies.
The reversal of spatial learning deficits by rapamycin (sirolimus) treatment in 
heterozygous Tsc2 mice [271] has suggested that mTOR inhibitors might also improve 
specific neurocognitive problems associated with tuberous sclerosis. In most of the 
patients with tuberous sclerosis scores for recall memory, that has been associated with 
mTOR activity15, increased while those for recognition memory, a domain not 
consistently associated with mTOR activity, did not. We included tests of executive 
skills because of the high rates of such deficits in tuberous sclerosis. More executive 
scores increased than decreased in patients with tuberous sclerosis and in those with 
sporadic lymphangioleiomyomatosis; observations that might reflect drug or practice 
effects.
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Adverse events were common and consistent with the known toxicity profile of 
sirolimus. The majority of patients experienced some mild/moderate adverse events and 
sirolimus had to be withdrawn due to toxicity in two patients. There were six serious 
adverse events including one patient with LAM who died from a respiratory infection. 
The toxicities seen in our study and that of Bissler et al. are broadly comparable. The 
pattern of toxicities appears to differ between those patients with sporadic LAM and 
those with tuberous sclerosis, with the LAM patients having more respiratory toxicities 
and those with tuberous sclerosis more metabolic toxicities. This may reflect 
underlying differences in organ involvement but the effects of haploinsufficincy in the 
TSC genes may influence toxicity in patients with tuberous sclerosis. Sirolimus is a 
relatively toxic drug with frequently occurring side effects of mild to moderate severity 
but also rarely occurring toxicities that are potentially life threatening such as interstitial 
peumonitis. This raises important questions with regard to the risk/benefit analysis of 
sirolimus use in the treatment of tuberous sclerosis and LAM.
This study has important limitations including the small sample size, the inclusion of 
patients with two conditions (tuberous sclerosis and sporadic LAM) with linked but 
separate aetiologies, the lack of a control group and that 6 of the 16 patients who were 
recruited did not undergo the 24 month evaluation. The primary endpoint was the 
response of AMLs as defined by RECIST criteria and the clinical significance of a 
reduction in AMLs size needs to be established. The small sample size particularly 
restricts the conclusions that can be drawn from the secondary outcome measures. No 
biopsies were taken that would have allowed assessment of mTORCl modulation by 
sirolimus and of possible mechanisms of reduction in AML. The reduction in AML size 
may reflect an induction of apoptosis, a decrease in cell size, an inhibition in 
proliferation, interference in angiogenesis or other mechanisms.
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Model systems suggest that TSC 1/2 deficient cells are ‘addicted’ to the mTORCl 
pathway [289, 290]. However, this clinical study and others highlight the limitations of 
sirolimus in terms of AMLs response and effects on lung function. Not all AMLs 
respond, the degree of response is variable, incomplete and largely reversible on 
cessation of drug treatment.
Against many cell types, sirolimus is mainly a cytostatic agent and its efficacy may be 
compromised by effects on feed back loops and crosstalk between intracellular 
signalling pathways. Also, sirolimus would not influence mTOR independent 
consequences of TSC 1/2 deficiency nor sirolimus resistant mTOR functions.
Alternative strategies to target TSC 1/2 deficient cells that potentially overcome these 
problems include the use of:
• drug combinations;
• alternative mTORCl inhibitors; and
• agents that target processes downsteam of mTORCl.
Inhibition of mTOR can relieve inhibitory feedback to other signalling molecules such 
as ERK or AKT and up regulation of compensatory pathways may allow ‘addiction 
bypass’ and attenuate the efficacy of mTOR inhibitors. This might be overcome by the 
use of multiple agents to target differences in a pathway [291] or by the use of drugs 
that interact with multiple targets [264].
ATP competitive mTORCl and mTORC2 inhibitors have greater effects on cell 
proliferation and induction of apoptosis than sirolimus in a variety of cell types, both in
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vitro and in vivo. This increased efficacy has been attributed to increased inhibition of 
mTORCl and mTORC2 as well as suppression of sirolimus-resistant functions [292]. 
However, use of these agents in animal models or patients has not been reported.
TSC 1/2 deficient cells appear to be highly sensitive to some forms of stress. The cells 
have an altered metabolic phenotype and exhibit a metabolic inflexibility that results in 
glucose addiction [111, 122]. The cells are also highly sensitive to other forms of stress 
which may reflect an inability to down regulate mTORCl activity in response to stress. 
TSC 1/2 deficient MEFs exhibit increased basal levels of ER stress compared to wild 
type cells and the use of drugs which increase ER stress is associated with a selective 
increase in apoptosis in the TSC 1/2 deficient cells in culture [194, 195]. However, 
experimental use of nelfinavir, a HIV protease inhibitor that is known to induce ER 
stress [293], did not appear to shrink or prevent renal tumours in transgenic mouse 
models (Dr Ming Shen, personal communication)
TSC 1/2 deficiency may be a biomarker of responsiveness to mTOR inhibition, not only 
in the context of tuberous sclerosis and LAM but also in sporadic cancers. Small 
mutations in TSC I have been demonstrated in bladder cancer (16% c [294] and in TSC2 
in pancreatic neuroendocrine tumours (8.8% of tumours) [295]. Decreased expression 
of either TSC1 or TSC2 mRNA has been noted in acute myeloid leukaemia [296], 
endometrial cancer [297] and breast cancer [298] and this has been associated with 
promoter hypermethylation. Loss of heterozygosity for either TSC1 or TSC2 has been 
demonstrated in bladder cancer [294] and lung cancer [299] and the possibility of a role 
of haploinsufficncy in TSC1 or TSC2 has been suggested. Phosphorylation of TSC2,
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leading to probable inhibition of function, mediated either by ERK or Akt has been 
demonstrated in breast, colon, endometrial and papillary renal cancer [72].
5.14.2 Conclusion
Our trial represents an early example of therapeutic targeting of a signalling pathway in 
Mendelian and sporadic disorders that share a common molecular pathology. The high 
response rate seen in the trial underscores the potential for effective targeted treatment 
when the setting is one of relative molecular homogeneity. Although our findings are 
based upon a small number of patients in a non-controlled open label trial, they suggest 
that mTOR inhibition may ameliorate some aspects of tuberous sclerosis and LAM and 
that larger controlled trials are warranted.
Very recently, the mTOR inhibitor, everolimus, has been approved by the American 
Food and Drug Administration for patients with SEGAs associated with tuberous 
sclerosis who require therapy but are not candidates for surgical resection on the basis 
of the single-arm open label trial of Krueger et al [280]. However, how mTOR 
inhibition will effect the long term outcome in this patient group remains unclear. The 
clinical trails database http://www.clinicaltrials.gov lists several completed, ongoing or 
approved trials of rapalogs for AMLS, brain lesions, epilepsy, lung disease and skin 
disease in tuberous sclerosis or lymphangioleiomyomatosis (table 11).
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Table 11: Clinical trials of rapalogs in tuberous sclerosis or
lymphangioleiomyomatosis
Identifiers Patient
group
Recruitment
target
Drug Trial deign Primary outcome 
measure
NCT00790400
Exist-2
Tuberous 
Sclerosis or 
Sporadic LAM
99 Everolimus
(RAD001)
Randomized, Double Blind, 
Placebo Control, Crossover 
Assignment, phase III
AML response rate
NCT00457964 Tuberous 
Sclerosis or 
Sporadic LAM
30 Everolimus
(RAD001)
Non-Randomized, Open Label, 
Uncontrolled, Single Group 
Assignment, phase II
AML burden
NCT00126672 Tuberous 
Sclerosis or 
Sporadic LAM
36 Sirolimus Non-Randomized, Open Label, 
Uncontrolled, Single Group 
Assignment, phase II
AML response rate
NCTO1059318 LAM 20 Everolimus
(RAD001)
Non-randomized, Open Label, 
Within-patient Multiple Dose- 
escalation, phase II
Safety, PK and PD 
endpoints
NCT00414648 LAM 120 Everolimus
(RAD001)
Randomized, Double Blind 
(Subject, Outcomes Assessor), 
Placebo Control, Parallel 
Assignment, phase III
Lung function, adverse 
events
NCT01031901 Tuberous 
Sclerosis or NF1
60 sirolimus Randomized, Double Blind, 
Placebo Control, Parallel 
Assignment, phase 1
Sirolimus levels
NCT00411619 Tuberous
Sclerosis
20 Everolimus
(RAD001)
Non-Randomized, Open Label, 
Uncontrolled, Single Group 
Assignment, phase V\ 1
SEGA response rate
NCT00789828 Tuberous
Sclerosis
99 Everolimus
(RAD001)
Randomized, Double Blind, 
Placebo Control, Crossover 
Assignment, phase III
SEGA response rate
NCTO 1070316 Tuberous
Sclerosis
20 Everolimus
(RAD001)
Non-Randomized, Open Label, 
Uncontrolled, Single Group 
Assignment, phase l/II
Reduction in seizure 
frequency
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Identifiers Patient
group
Recruitment
target
drug Trial design Primary outcome 
measure
NCT00411619 Tuberous
Sclerosis
20 Everolimus
(RAD001)
Non-Randomized, Open Label, 
Uncontrolled, Single Group 
Assignment, phase 1/11
SEGA response rate
NCT00789828 Tuberous
Sclerosis
99 Everolimus
(RAD001)
Randomized, Double Blind, 
Placebo Control, Crossover 
Assignment, phase III
SEGA response rate
NCTO 1070316 Tuberous
Sclerosis
20 Everolimus
(RAD001)
Non-Randomized, Open Label, 
Uncontrolled, Single Group 
Assignment, phase I/II
Reduction in seizure 
frequency
Clinical trials o f rapalogs in tuberous sclerosis or lymphangioleiomyomatosis currently 
listed on http://www.clinicaltrials.gov
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Chapter 6: Small-molecule signal-transduction inhibitors as targeted 
therapeutic agents for single-gene disorders
6.1 Introduction
Mutations affecting over 2,000 of the 20,000 or so genes in the human genome have 
been linked so far to specific inherited diseases, most of which are rare. Many of the 
genes involved encode components of intracellular signalling pathways that regulate 
processes such as the growth, proliferation, differentiation, and survival or programmed 
death of cells during development and the maintenance of tissues and organs. Mutations 
that change the function of genes encoding signalling proteins thereby cause disorders 
ranging from birth defects to cancer. For Mendelian disorders, the essentially causal 
relationship between mutation and disease may present direct opportunities to 
therapeutically manipulate intracellular signalling.
6.2 Targeting tumours
Mutations in oncogenes and tumour suppressor genes result in the deregulation of 
intracellular signalling pathways that control apoptosis, proliferation, angiogenesis, 
metabolism, stress responses and other cellular functions. In recent years, many agents 
that manipulate intracellular signalling have been developed as potential cancer 
treatments. The successes of signal transduction inhibitors such as imatinib, gefitinib 
and erlotinib show this approach can yield valuable clinical benefit, but experience of 
their use has highlighted the importance of patient selection [300]. When signal- 
transduction inhibitors have been used in patient groups defined by tumour histology, 
the results have been generally disappointing, reflecting underlying heterogeneity in 
molecular pathology. In contrast, successes have occurred when these drugs have been 
used against tumours that share a specific molecular defect. Examples include 
gastrointestinal stromal tumours, most of which carry mutations in the c-kit oncogene,
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the target for imatinib, and non-small cell lung cancer in which specific mutations in 
epidermal growth factor receptor (EGFR) predict response to gefitinib or erlotinib [301, 
302]. Such tumours exhibit a dependence upon a specific aberrant signalling pathway or 
gene product, and this phenomenon has been termed “oncogene addiction” or “tumour 
suppressor hypersensitivity”, depending on the nature of the responsible gene [303]. In 
these settings, suppressing oncogenes activity or restoring tumour suppressor activity 
has been shown to be potentially deleterious to a cancer cell.
A related approach utilises the concept of synthetic lethality. Two genes have a 
synthetic relationship when inhibition or mutation of either gene alone does not cause 
loss of viability, but simultaneous inhibition or mutation of both genes results in 
reduced cell viability [304]. Synthetic lethality underlies the rationale for the use of 
Poly(ADP-Ribose) Polymerase 1 (PARP) inhibitors in BRCA 1 or 2 deficient tumours 
[305]. PARP is required to repair single stranded DNA breaks. If PARP is inhibited 
single stranded DNA breaks persist and during DNA replication are converted to double 
stranded breaks. These can normally be repaired by BRCA 1/2 mediated homologous 
recombination which is a relatively error free process. In the absence of functional 
BRCA 1/2 the double stranded DNA breaks persist or are repaired by error prone non- 
homologous end joining, leading to cell death. Many synthetic lethal relationships 
represent examples of functional buffering where when one molecular function, gene or 
protein is lost, another can readily be used to mitigate any effects that could limit either 
cell survival [306]. Exploiting oncogene or tumour suppressor gene induced lack of 
flexibility in metabolic or stress responses can be thought of as a synthetic lethal 
approach where multiple targets involved in a cellular process may be synthetically 
lethal with the mutated oncogene or tumour suppressor gene.
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Tumours arising in specific Mendelian tumour predisposition syndromes share at least 
one key molecular abnormality, for example, mutations in the tumour suppressors 
TSC1/2 in tuberous sclerosis, VHL in Von Hippel-Lindau disease or NF1 in 
neurofibromatosis type 1. This relative molecular homogeneity may facilitate selection 
of therapeutic agents to exploit oncogene addiction/tumour suppressor hypersensitivity 
or synthetic lethality.
Trials of mTOR inhibitors in sporadic cancer have generally been disappointing. The 
rapalog temsirolimus has been licensed in the UK and USA as a treatment for advanced 
clear cell renal carcinoma following a phase III study that showed that temsirolimus 
improved overall survival compared to treatment with interferon. Median overall 
survival times in the interferon group and the temsirolimus group were 7.3 and 10.9 
months respectively. The objective response rate was 8.6%, among patients receiving 
temsirolimus, the proportion of patients with stable disease for at least 6 months or an 
objective response was 32.1% in this group [307]. VHL is mutated in 55% [308] and 
methylated in approximately 30% [309] of cases of clear renal cell cancer. The efficacy 
of mTOR inhibition in the clear cell renal cancer may, at least in part, be due to a 
reduction in the abnormally high HIF activity caused by VHL deficiency [310]. 
However, the objective response rate to temsirolimus in renal cancer is far below that 
seen in our trial. This may reflect that the tumours we treated were benign and do not 
exhibit the genomic instability of more malignant tumours, with the accompanying 
ability to develop drug resistance. However, it may also reflect the underlying 
homogeneity of addiction in the lesions we treated.
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6.3 Targeting the brain
Many Mendelian disorders are associated with cognitive deficits. Recently, interest has 
become focused on whether some of these deficits might be amenable to the therapeutic 
targeting of intracellular signalling pathways, even if this is started in adulthood.
de Vries and Howe hypothesized that neurocognitive deficits in tuberous sclerosis are a 
direct result of aberrant intracellular signalling and that tubers and seizures were 
therefore neither necessary nor sufficient to explain the observed neurocognitive 
phenotypes [8]. A corollary of this is that molecular modulation may improve or reverse 
such neurocognitive deficits. The beneficial effects of mTOR inhibition on cognitive 
function seen in tuberous sclerosis animal models are consistent with the results of our 
trial. Larger placebo controlled trials of mTOR inhibition in tuberous sclerosis, where 
cognition function is the primary outcome, are currently being planned in the USA and 
UK.
A number of neurocognitive deficits occur in Fragile X syndrome [311]. This condition 
results from a trinucleotide repeat expansion in the promoter of the FMR1 (fragile X 
mental retardation-1) gene [312] which leads to transcriptional silencing of FMR1 and 
reduced expression of the FMR1 protein (FMRP) [313]. FMRP is an RNA binding 
protein which modulates protein synthesis through mechanisms including inhibition of 
group 1 metabotropic glutamate receptor (mGluRl and mGluR5) mediated mRNA 
translation [314]. mGluR antagonists ameliorated memory impairments in 
Si Drosophila model of Fragile X [315] and a number of Fragile X phenotypes in mice 
[316, 317]. Very preliminary studies in humans using lithium [318] or fenobam [319], 
mGluR5 antagonists, are encouraging but properly powered trials are required.
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The difficulties of extrapolating from mouse models to humans and of conducting trials 
in the area of cognitive function have been illustrated in a trial of statins in 
neurofibromatosis type 1 (NF1) [320]. This condition is characterised by a number of 
neurocutaneous manifestations, including tumour growth and the frequent occurrence of 
intellectual disability and specific neuropsychological deficits. Neurofibromatosis type 
1 is caused by mutations in the NF1 gene, which encodes a GTPase activating protein 
whose normal role is to regulate RAS signalling. [321] Increased RAS signalling has 
been implicated in the neuronal plasticity defects and spatial learning and attention 
problems seen in neurofibromatosis type 1 mouse models [322, 323]. RAS signalling 
can be inhibited by farnesyl transferase inhibitors and 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase inhibitors, which block the isoprenylation required 
for RAS activity. Treatment of neurofibromatosis type 1 mouse models with these 
agents for just a few days was found to lead to a reversal of cognitive function deficits 
[324]. On the basis of these findings, Krab et al [320] conducted a clinical trial to assess 
the effect on cognitive function of the HMG-CoA reductase inhibitor simvastatin in 
children with NF1. Sixty-two children were randomised to receive either simvastatin or 
placebo for 12 weeks. However, no significant differences were observed in the primary 
outcome measures of cognitive function. The authors reflected that this study had a 
number of limitations. The lack of effect may reflect an inadequate treatment duration 
or failure to achieve adequate drug concentrations in the brain. The placebo group 
performed better in a number of cognitive function tests and there was a relatively high 
amount of missing data.
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Cognitive function is inherently complex and multifaceted. In trials assessing cognitive 
function careful thought must be given to the selection of the cognitive tests performed, 
to maximise the chance of capturing changes. Equally, consideration must be given as 
to whether changes in cognitive function will result in clinically meaningful benefits to 
the patient and that the potential risks of taking an investigational drug are justified.
Inhibition of mTORCl has also been proposed as a therapeutic strategy for 
neurodegenerative conditions such as Huntington disease where the formation of 
abnormal protein aggregates may contribute to pathogenesis [325]. Inhibition of 
mTORCl with sirolimus in mouse models of Huntington disease enhanced the 
clearance of these proteins, possibly by up regulating autophagy, and ameliorated 
behavioural abnormalities [326].
6.4 Targeting tissue integrity
The maintenance of cell and tissue integrity requires a balance between cell death and 
division, control of cell differentiation and regulated interplay between cells and the 
extracellular matrix.
Marfan syndrome is characterised by abnormalities of the skeletal, cardiovascular and 
ocular systems and affects approximately 1 in 20 000 individuals [327]. It is caused by 
mutations in the FBN1 gene, which encodes fibrillin-1. This microfibril protein 
contributes to the mechanical integrity of organs and the vasculature. Aortic root 
dissection is a major cause of mortality in patients with Marfan syndrome. Recent 
studies have shown that aortic aneurysm in Marfan syndrome may arise not simply as a 
result of inherent weakness of connective tissues due to deficiency of fibrillin-1 but also
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because of defective interaction between fibrillin-1 and transforming growth factor beta 
(TGFp), leading to impaired tissue maintenance [328]. The TGFp family of growth 
factors regulate many cellular processes such as proliferation, differentiation and 
survival. TGFp is normally sequestered by fibrillin-1 and is released in a tightly 
controlled manner. Deficiencies of fibrillin-1 may thereby lead to excessive TGFp 
activity and promote processes such as matrix degradation, which may contribute to 
vascular pathology [329].
Analysis of Fbnl knockout mouse models that develop fatal aortic aneurysms showed 
up regulation of TGFp signalling in affected tissue, and treatment of these mice with 
TGFp neutralising antibodies reduced aortic root dilatation [330]. TGFp-neutralising 
antibodies are not currently available for clinical use in humans. However, another way 
of reducing TGFp signalling is to target the angiotensin pathway with a small-molecule 
angiotensin II type 1 receptor blocker such as losartan, a widely used antihypertensive 
agent. ATI-receptor blockade decreases TGFP-mediated intracellular signalling by 
incompletely understood mechanisms that may involve a direct effect on TGFp 
synthesis and modulation of cross-talk between signalling pathways [331, 332]. Habashi 
et al. treated Fbnl knockout mice with losartan, the p-blocker propranolol or placebo 
[333]. The doses of losartan and propranolol were titrated to obtain comparable changes 
in blood pressure. Propranolol reduced the aortic root dilatation compared with placebo, 
but losartan completely inhibited aortic root dilatation, and losartan-treated animals 
were indistinguishable from wild-type controls. In a small-cohort study of 18 patients 
with Marfan syndrome, treatment with an angiotensin II type 1 receptor blocker was 
associated with a dramatic slowing in the rate of aortic root dilatation [334]. In light of
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these promising results, a number of clinical trials of losartan for Marfan syndrome are 
being undertaken [335-339].
TGFp inhibition may have a therapeutic role in a wider range of inherited conditions. 
Increased TGFp activity has been implicated in the pathogenesis of the X-linked 
Duchenne and Becker muscular dystrophies, caused by mutations in the DMD gene. 
These conditions are characterised by progressive skeletal muscle weakness and 
wasting. The more severe Duchenne form is usually fatal by early adult life. Early in the 
disease both muscle cell death and regeneration are seen, but regeneration slowly fails 
and fibrogenesis occurs [340]. This process has been linked to increased TGFp activity 
[341, 342]. Treatment of DMD knockout mice with losartan resulted in improvement of 
muscle architecture and function by maintaining muscle regeneration [342]. These 
findings have led to proposals for clinical trials of losartan for the human disease.
6.5 Treatment in utero
Many Mendelian disorders are characterised by congenital anomalies, which reflect 
abnormal development in utero. Recent studies in mouse models have suggested that 
molecularly targeted therapies might be used in utero to treat malformation syndromes. 
Apert syndrome is characterised by craniosynostosis and syndactyly of the hands and 
feet. It is caused by activating mutations in fibroblast growth factor receptor 2 (FGFR2) 
gene, most commonly S252W [343]. Such mutations up regulate a number of 
downstream signalling pathways including the mitogen activated protein kinase 
(MAPK) pathway [344]. Shukla et al. [345] developed a mouse model of Apert 
syndrome in which embryonic expression of a mutant FGFR2 allele led to 
craniosynostosis. Introduction of a short hairpin RNA (shRNA) complementary to the
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mutant allele prevented its expression, normalised signalling in the MAPK pathway, 
and corrected the phenotype. The therapeutic use of RNA interference to knock down 
the expression of target genes is an exciting prospect, but issues of delivery and safety 
will have to be overcome [346]. However, Shukla et al. [345] also treated pregnant 
transgenic mice with U0126, a small-molecule MEK1/2 inhibitor, and this led to 
complete repression of craniosynostosis in affected embryos. Cranial abnormalities 
emerged in the postnatal period, but were ameliorated by reinitiating treatment with 
U0126. MAPK pathway inhibitors may have a role in other inherited disorders that 
exhibit increased MAPK signalling such as the phenotypically related conditions 
cardiofaciocutaneous, Costello and Noonan syndromes, all caused by mutations in 
genes encoding components of the MAPK pathway [347]. However, significant 
difficulties exist for the translation of in utero therapy to the clinical setting, including 
the need for sufficiently early prenatal diagnosis and the risk of drug-related 
teratogenicity.
6.6 Limitations to molecularly targeted therapy
Simply inhibiting one component of a perturbed signalling pathway may fall far short of 
restoring normal signalling, with its nuanced responses to multiple stimuli, and in 
practice it is difficult to titrate dose against molecular response resulting in limited 
efficacy and in toxicity. The cellular pharmacodynamics may be very different for 
heterozygous as opposed to wild type cells resulting in a different toxicity profile 
between patients with a single gene disorder and the general population. The multi­
organ involvement seen in many tumour predisposition disorders may further contribute 
to an altered toxicity profile. Many signal transduction inhibitors are “promiscuous” 
drugs, inhibiting multiple signalling molecules, and these off-target effects may also
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contribute to a wide side-effect profile. Feedback mechanisms and cross-talk 
characterise many signalling networks and may lead to unintentional effects when a 
pathway is targeted. Functional redundancy between pathways may also limit drug 
efficacy. Combination therapy or the use of “promiscuous” drugs to target multiple 
signalling pathways or multiple components of the same pathway may overcome some 
of these difficulties. As not all types of signalling molecules are currently “drugable”, 
new classes of drugs that target protein/protein interactions or protein/DNA binding are 
likely to be required to expand the range of genetic diseases amenable to a molecularly 
targeted approach.
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Chapter 7: Challenges to the clinical development of molecularly 
targeted therapy for single gene disorders
7.1 Introduction
Individual inherited single gene disorders are often rare, but collectively they affect a 
significant proportion of the population. Effective treatments for these diseases 
represent an area of unmet medical need and, whilst an increased understanding of the 
molecular pathology underpinning these disorders has presented new therapeutic 
opportunities, there are significant challenges in developing drugs to treat these 
conditions. The patient population is usually small and geographically dispersed and 
may include vulnerable groups such as children or people with intellectual disability. 
The diseases are often multi-system with variable expression and the molecular biology 
underlying the disease and response to treatments is complex.
7.2 Clinical trials in rare genetic diseases
The Committee for Medicinal Products for Human Use (CHMP) has produced 
guidelines for clinical trials in small populations which recognise that the conduct, 
analysis, and interpretation of studies in rare conditions may be constrained to varying 
degrees [348].
Hierarchies of evidence have been described which usually place in order:
• meta-analyses of randomised controlled clinical trials;
• individual randomised controlled trials;
• meta-analyses of observational studies;
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• individual observational studies;
• published case-reports;
• anecdotal case-reports; and
• opinion of experts in the field.
All such forms of evidence provide some information. For rare disorders it may not be 
feasible to perform randomised control trials. Potentially, the combined evaluation of 
single case studies may be the only way to accumulate evidence. In such studies, 
standardised treatment conditions and data collection would facilitate systematic 
review.
A number of trial designs especially lend themselves to studies with small numbers of 
participants, including single subject (n-of-1) designs, sequential designs and response 
adaptive designs. The small number of potential participants in rare disease trials may 
be insufficient for a classical (frequentist) trial based on hypothesis testing at accepted 
statistical levels of confidence. One option is to relax the type I and type II error 
boundaries. An alternative is to use Bayesian methods [349, 350]. Here, a power 
calculation is not required, the data can be analysed as it accumulates and a probability 
range would be obtained even with a small number of participants, albeit not at 
conventionally accepted levels of certainty. But a lower degree of certainty in a result is 
better than no result at all.
The credibility of study results may be increased if a clear chain of events can be 
established (for example, drug exposure to molecular target occupancy, evidence of 
target modulation, biomarkers of response and then clinical outcome). Bradford-Hill’s
123
criteria for determining causality in observational studies may be helpful [351]. These 
include:
• consistency of association;
• biological gradient: Is there a dose response effect?
• specificity of association;
• biological plausibility;
• strength of association.
Surrogate markers of outcome may have to be used as alternatives to clinical endpoints 
to allow a study to be carried out. Use of a biomarker as a valid surrogate endpoint 
requires it to be reasonably likely -  based on epidemiologic, pathological, or other 
evidence -  to predict benefit. However, validation of surrogate endpoints is often 
difficult, particularly in rare diseases.
In trials in rare disorders it is particularly important that every patient participating in a 
study contributes as much information as possible and that opportunities to perform 
related translational studies are exploited fully. The restricted patient pool may preclude 
multiple studies. As single gene disorders are often multisystem disorders thought needs 
to be given to including a range of endpoints to maximise the information gained from 
each person entered into a trial. To reflect this multisystem involvement the team 
involved in the design and conduct of a trial may need to be multi-disciplinary.
Slow participant accrual is likely to be a problem in trials in rare conditions. In the UK, 
the care of people, particularly adults, with genetic multisystem disorders is often
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fragmentary and poorly co-ordinated and this is reflected in a lack of infrastructure to 
carry out clinical trials in these conditions. Patient registers will have an important role 
by facilitating recruitment and providing information on the natural history of a disease. 
Regional clinical genetic services have already developed registers for some disorders 
and recently the families of patients affected by Duchenne muscular dystrophy were 
instrumental in setting up a national register of patients and their genotypes specifically 
to facilitate clinical trials [352].
The likely small sample sizes in rare disease trials means minimising loss to follow up 
is important. Bio-noise, the sum of avoidable and unavoidable non-systematic errors in 
the design and conduct of a trial, is a particular problem. Therefore, minimisation of 
avoidable errors such as those that occur through loss to follow up is of great 
importance. Loss to follow up may be reduced by scheduling visits at reasonable 
intervals and at times convenient to patients, providing transport where necessary 
making adequate provision for parents and/or carers. Involving patient groups at an 
early stage in the trial design may help to ensure the trial is acceptable to potential 
participants.
Clinical trials in rare diseases will often require international co-operation and co­
ordination and this would benefit from further simplification and standardisation of 
regulatory and ethical approval processes. Given the restricted numbers of potential 
participants, it is important that careful thought is given as to which drugs are to be 
tested and that the research community communicates to prevent unnecessary 
duplication of research.
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Cost is a major challenge in the development of novel agents. Pharmaceutical 
companies may elect to explore drug development in some rare but biologically 
informative conditions to open niche markets or to gain insights into disease processes 
relevant to more common conditions. World wide a number of programmes have been 
introduced to promote the development of ‘orphan’ medicinal products for rare 
diseases. The European Union defines an ‘orphan’ medicinal product as a product 
intended for the diagnosis, prevention or treatment of life-threatening or chronically 
debilitating conditions that affect no more than 5 in 10,000 people in the European 
Union (EU), or one which, for economic reasons, would be unlikely to be developed 
without incentives. The EU ‘orphan’ medicinal products programme provided 
community wide economic incentives to pharmaceutical companies such as market 
exclusivity provision,, regulatory fees waivers and protocol assistance.
Most drugs currently in trials for genetic disorders have already been used to treat other 
sporadic conditions. It is likely that repositioning of such agents will remain the most 
realistic strategy for the future treatment of many of the disorders that constitute the 
workload of clinical genetics services. This repositioning may be viewed by 
pharmaceutical companies as a relatively low risk strategy to optimise product pipelines 
but conflict may arise between the interests of these companies and those of healthcare 
purchasers with regards the benefits of repositioning older, well established drugs, 
nearing the end of their patent period compared with newer, more expensive 
derivatives.
Despite programmes to support orphan medicinal product development, economic 
considerations mean that for many single genes disorders translational research will
126
have to be driven from outside the pharmaceutical industry. Clinical and laboratory 
genetics services have been quick to translate knowledge of the human genome into 
diagnostic advances. They should now accept the challenge of delivering the therapeutic 
advances in inherited disorders that were anticipated by the Human Genome Project.
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Appendices
Appendix 1: Sample patient information sheet for participants
version 18 (01/09/05) 
A trial of the efficacy and safety of sirolimus (rapamycin) in 
tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM 
(TESSTAL).
INFORMATION SHEET FOR POTENTIAL PARTICIPANTS WHO HAVE 
TUBEROUS SCLEROSIS
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss 
it with others if you wish. Ask us if there is anything that is not clear or if you 
would like more information. Take time to decide whether or not you wish to 
take part. Thank you for reading this.
1. What is the purpose of the study?
This study will examine the safety and efficacy (beneficial effects) of the drug 
sirolimus in people who have benign (not cancerous) growths in the kidneys 
called angiomyolipomas (AMLs) and either or both of the related conditions 
tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM)).
Sirolimus is also known as rapamycin. Sirolimus has been used for over 4 years 
in patients having organ transplants but, until now, has not been used to treat 
AMLs or TSC. Research has suggested that sirolimus may be helpful in treating 
AMLs and the related conditions TSC and lymphangioleiomyomatosis of the 
lungs (LAM).
2. Why have I been chosen?
You have been invited to participate in this study because you have tuberous 
sclerosis (TSC) and in the past have had scans that have shown a benign fatty 
lump or lumps in your kidney(s) called angiomyolipomas. Your doctor has 
considered that you are eligible for the study as you are mildly affected by the 
tuberous sclerosis (and do not have a learning disability as some patients do) 
but the lumps in your kidney(s) are big enough to detect a response to the 
treatment, if one occurs.
3. Do I have to take part?
No, it is entirely up to you to decide whether or not to take part. If you do decide 
to take part you should keep this information sheet and you will be asked to sign 
a consent form. If you decide to take part you are still free to withdraw at any
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time and without giving a reason. A decision to withdraw at any time, or a 
decision not to take part, will not affect your future medical care in any way.
4. What will happen to me if I take part?
Before you start the drug one of the study doctors will examine you and you will 
have blood and urine tests. If the alteration in the gene responsible for TSC in 
yourself is not known this will be looked for. If we need to look for a genetic 
alteration we will give you a separate information sheet and ask you to sign a 
separate consent form. You will have a MRI scan of your kidneys to accurately 
measure the angiomyolipomas. You will have a chest X-ray. Females will also 
have a CT scan of the lungs, as these organs are sometimes affected by TSC 
in women (unless you have already had a recent CT scan of the lungs for which 
the result is available). You will also have a MRI of your brain and be asked to 
do some tests to assess your concentration, learning and memory. If you have 
epilepsy we will give you a diary to record any seizures. These are ’baseline’ 
tests which will help us to look for positive effects or side effects of the sirolimus 
as the trial progresses. As a result of these baseline tests we may find a reason 
why you cannot take part in the study and this will be shared with you if this is 
the case.
You will need to see the study doctor after three weeks, two months, four, six, 
nine, twelve, eighteen and twenty four months during the study. We can 
reimburse you reasonable travel expenses for all visits. At each of these visits 
you will have further blood and urine tests. To follow the effect of the drug on 
your kidneys you will have further kidney MRI scans after two, six, twelve, and 
twenty four months (four more times) on sirolimus treatment. After 12 months in 
the study you will have another MRI scan of your brain. After four months and 
after twelve months you will be asked to do further tests of concentration, 
learning and memory. All participants will have basic lung function (breathing) 
tests at the start of the study, after three weeks and then at two, four, six, nine, 
twelve, eighteen and twenty four months (eight more times). If you are a female 
with affected lungs you will have more detailed basic lung function (breathing) 
tests at the first study visit and at 4 months, 6 months, 12 months and 24 
months and you will also have a further CT scan of the lungs at the end of the 
study. In between visits a study doctor will telephone you to ask about any 
changes in medication, side effects or other medical problems. We will call after 
one week, one and a half months, five months, seven and a half months, ten 
and a half months, fifteen months, twenty one months and 25 months.
Sirolimus comes as a liquid which you take by mouth. You will receive a low 
dose of sirolimus for the first two months. If your kidney scan does not improve 
by the end of these two months you will receive a higher dose for the rest of the 
trial. During the trial sirolimus will be stopped if your scans get worse, if the 
AMLs haven’t shrunk at all after 4 months on the higher dose or if you have 
significant side effects from the sirolimus (section 8 of this information sheet 
lists some of the potential side effects of sirolimus). We will discuss with you 
reducing the dose or stopping the sirolimus if your angiomyolipomas shrink to 
less than a quarter of their original size. Using a blood test at each visit, we will
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monitor the level of sirolimus in your blood and measure the levels of red and 
white blood cells, kidney function, liver function and fats in the blood. This will 
require us to take 30 mis of blood (four small tubes, equal to about 2 
tablespoons) at each visit.
The whole study will last two years although you may not need to take sirolimus 
for the whole of this time.
5. What do I have to do?
Sirolimus comes as a liquid which you take by mouth. When you take sirolimus 
you can draw up the dose using a plastic syringe which we will provide and then 
mix it with a glass of water or orange juice. After you have drunk this you should 
drink another glass of water or orange juice straight away.
When you are taking sirolimus we will ask you to inform us before taking any 
new medication. You should avoid grapefruit juice because this increases the 
levels of sirolimus in the blood.
You should not give blood, become pregnant or breast feed while you are on 
the sirolimus. Women will be asked to have a pregnancy test before taking part 
to exclude the possibility of unexpected pregnancy and will also have a 
pregnancy test at each visit. If you are male or female you will be asked to use 
a reliable form of contraception for the duration of the study and for 12 weeks 
after you stop taking sirolimus. We will discuss with you and help you decide 
what will be the most suitable form of contraception given the options available.
It will be important to take your medication regularly and at the same time in 
relation to food. We will ask you to take the sirolimus straight after breakfast. 
You will have monitoring blood tests at the appropriate times. In order to 
measure the fat levels in the blood accurately we need fasting samples. This 
means we will ask that you do not eat from midnight of the night before a study 
visit until you have had your blood tests done the next morning. We will ensure 
that your blood tests are done immediately when you arrive for a study visit so 
that you can then have some breakfast.
If you have private health insurance you will need to inform your insurers 
that you are in a trial. 
6. What is the drug or procedure that is being tested?
Sirolimus was first used in 1999 and has been given to over 4000 patients. It is 
currently used in patients who have received a kidney transplant to help prevent 
rejection. Studies in the laboratory predict that it will have a beneficial effect in 
patients with TSC who have angiomyolipomas. This study is designed to assess 
the safety and hopefully beneficial effects in patients with TSC and 
angiomyolipomas.
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7. What are the alternatives for diagnosis or treatment?
There are currently no drug treatments for angiomyolipomas. Lesions that grow 
very large or bleed are normally treated by having their blood supply blocked 
during a minor operation or they are removed surgically with a bigger operation. 
These treatments can still be performed during the study should they become 
necessary. Your normal treatment for other complications of TSC should not be 
affected.
8. What are the side effects of any treatment received when taking 
part?
For any drug there are possible side effects. Occasionally, sirolimus may cause 
a reduction in blood cells leading to anaemia, increased risk of infection or 
delayed wound healing. Some people receiving the drug develop raised 
cholesterol or other blood fats which may need a low fat diet or extra tablets. 
More rarely, patients have developed a pneumonia-like reaction. Other side 
effects that have been seen include abdominal discomfort, diarrhoea, a fast 
heart rate, a decrease in the level of elements like potassium in the blood, joint 
pain, acne and mouth ulcers. All of the above effects should be detected by the 
monitoring procedures and usually go back to normal if the drug is stopped.
Sirolimus can also cause blood clotting problems that can result in either an 
increased risk of bleeding or the formation of abnormal blood clots (e.g. in the 
legs or lungs).
As sirolimus has not been used to treat many people with TSC, there may be 
other side effects not previously seen. For example, there is a theoretical risk 
that shrinking angiomyolipomas may make them more likely to bleed. Similarly, 
if you have epilepsy the drug could make this worse or it could trigger a seizure 
in someone who has been previously seizure free. If this happens your driving 
licence could be withdrawn. However, to date neither increased bleeding nor 
worsening epilepsy have been seen in TSC patients who have already received 
sirolimus. However, the numbers treated so far are too small to discount these 
risks. There is no evidence that sirolimus has any effect on concentration, 
learning and memory but this will be carefully monitored as part of the study. 
You will be given a card with emergency contact numbers and the study details 
to carry while you are in the study.
As sirolimus can affect wound healing we would recommend that the drug is 
stopped at least two weeks before an operation and not re-started until at least 
two weeks after an operation. Therefore, you should contact a study doctor if 
you have had or are about to have an operation. Similarly, if you have an 
accident or any treatment in A&E that involves a cut to the skin or stitches then 
please contact a study doctor for advice about sirolimus.
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If you develop signs such as fever (a temperature greater than 38 degrees 
Celsius which is the same as 100.4 degrees Fahrenheit), sore throat, 
abdominal pain, bleeding, bruising or mouth ulcers you should seek immediate 
medical advice. You could contact your GP, attend at your local A&E 
department or contact a study doctor.
You can contact a study doctor between 9 am and 5 pm Monday to Friday on:
029-20-744672
For emergencies outside these hours you may contact a study doctor via the 
switchboard at Brighton hospital on:
01273-696955
9. What are the possible disadvantages and risks of taking part?
In women who become pregnant, while on treatment with sirolimus, the drug 
may harm the unborn child. Pregnant women cannot take part in this study; 
neither can women who plan to become pregnant during the 2 year study 
period. Any woman who finds that she has become pregnant while taking part 
in the study should immediately contact the study doctor. We will ask for your 
consent to follow up any children who are born to women taking sirolimus in this 
study. This is not for research purposes but to allow any health problems in 
these children to be detected as early as possible and appropriate medical 
care arranged. Women who are breast feeding should not take part in the 
study as the drug can enter breast milk.
There is a possible risk that by suppressing the immune system sirolimus could 
increase the risk of cancers, such as of the lymphoid system and skin. Because 
of the potentially increased risk for skin cancer exposure to sunlight and UV 
light should be limited by wearing protective clothing and using a sunscreen 
with a high protection factor.
There is mild discomfort associated with the taking of blood samples as 
required in this study.
The MRI scan involves lying still for about 30 minutes in the scanner. Some 
patients experience a feeling of claustrophobia during MRI scans, though the 
scans themselves cannot be felt and are not harmful.
Having a chest X-ray and a CT scan does involve exposure to radiation. The 
dose of radiation associated with a chest X-ray is equivalent to about 3 day’s 
worth of background radiation i.e. the normal environmental radiation we are all 
exposed to. The dose of radiation associated with a CT scan is equivalent to 
about 12-24 months worth of background radiation. The total risk of harm from 
radiation from one chest X-ray and one CT scan is about 1 in 2800.
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In females it is possible that the lung CT scan will show evidence of lung 
involvement by TSC which was not already known to be present. If we discover 
that you are affected in this way, but have not been aware of it, we will give you 
full advice on what to do about this, how the lung changes will be monitored 
throughout the study and what other steps you should take after the study.
During treatment with sirolimus vaccination may be less effective and some 
types of vaccine (live vaccines such as BCG for tuberculosis, varicella-zoster 
[the virus that causes chickenpox and shingles] vaccine, yellow fever vaccine, 
measles, mumps and rubella [MMR] vaccine and the live type of poliomyelitis 
[polio] vaccine) cannot be given. Because of this, if you are likely to need 
vaccination e.g. for travel during the course of the study you will not be able to 
participate. People with LAM can have influenza (flu) vaccination and still 
participate in the study but because of taking sirolimus it is possible that this 
vaccine will be less effective.
10. What are the possible benefits of taking part?
We hope that sirolimus will shrink the angiomyolipoma(s) in your kidney(s). The 
information we get from this study may help us to improve treatment for other 
people with TSC or LAM.
11. What if new information becomes available?
Sometimes during the course of a research project new information becomes 
available about the drug that is being studied. If this happens, one of the 
doctors working on the study will tell you about it and discuss with you whether 
you can and want to continue in the study. If you decide to withdraw from the 
study, arrangements will be made for your standard care to continue. If you 
decide to continue in the study you will be asked to sign an updated consent 
form.
12. What happens when the research study stops?
If suitable, you may be able to continue sirolimus treatment after the study has 
ended, but we cannot guarantee this at the present time.
13. What if something goes wrong?
If taking part in this research project harms you, there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, 
then you may have grounds for a legal action but you may have to pay for it. 
Regardless of this, if you wish to complain, or have any concerns about any 
aspect of the way you have been approached or treated during the course of 
this study, the normal National Health Service complaints mechanism should be 
available to you.
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14. Will my taking part in this study be kept confidential?
If you consent to take part in the research the investigators may look at your 
medical records to aid with analysing the results. Your records may also be 
looked at by regulatory authorities to check that the study is being carried out 
correctly. Your name, however, will not be disclosed outside the participating 
hospitals, except to inform your GP and hospital consultant (if you have one) 
that you are participating in the study.
15. What will happen to the results of the research study?
The results of this research will be published in a medical journal. You will not 
be identified in any publications.
16. Who is organising and funding the research?
The study is being organised by doctors with special interests in tuberous 
sclerosis and lymphangioleiomyomatosis. It is being funded by the Tuberous 
Sclerosis Association and LAM Action. No doctor will receive extra payment for 
including you in the trial.
17. Who has reviewed the study?
Independent experts in TSC, kidney and lung disease have reviewed the study. 
The Thames Valley Multi-Centre Research Ethics Committee has also reviewed 
the study and has no objections on ethical grounds.
18. Contacts for further information
Further information about the study can be obtained from;
Thank you for considering this study.
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Appendix 2: Consent form
version 18 
(01/09/05)
A  tria l o f  th e  e f f i c a c y  a n d  s a fe ty  o f  s ir o lim u s  (ra p a m y c in ) in  tu b ero u s  
s c le r o s is  (T S C )  a n d  ly m p h a n g io le io m y o m a to s is  (L A M ). (T E S S T A L )
Participant Number:
CONSENT FORM
Please initial box
1. I confirm that I have read and understand the information sheet
dated 01.09.05 (version 18) for the above study and have had the opportunity 
to ask questions. □
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights 
being affected.
□
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Participant N um ber:
3. I understand that sections of any of my medical notes may be looked at by 
the health professionals undertaking this study, or by regulatory authorities 
where it is relevant to my taking part in the research. I give permission for 
these individuals to have access to my records.
6. I agree to my hospital consultant(s) being notified of my participation 
in this study
for females only
7. I agree that if I become pregnant whilst taking sirolimus any child born can be 
followed up in a medical clinic..
4. I agree to take part in this study.
5. I agree to my GP being notified of my participation in this study
Name of Patient Date Signature
Name of Person taking consent Date 
(if different from researcher)
Signature
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Researcher Date Signature
1 copy for patient; 1 for researcher; 1 to be kept with hospital notes
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Appendix 3: Drug interactions card
TESSTAL version 14 (12/01/05)
Sirolimus and other drugs
Sirolimus can interact with other drugs. There are some drugs that shouldn’t be used in 
combination with sirolimus and there are other drugs that should be avoided if possible 
or used with caution. Both types of drug are listed overleaf.
All drugs have a generic name; most drugs also have a trade name. For example, 
sirolimus is a generic name and Rapamune is its trade name. Both the generic name and 
the trade name (if the drug has one) will be displayed on the medication's packaging. On 
the list overleaf the generic name and the trade name (where applicable) are given.
We would be grateful if you could contact a study doctor if you start any new 
medication (this also includes over the counter medication and herbal remedies). 
Please also contact us if either you or one of your doctors would like advice about 
the use of other drugs in combination with sirolimus.
Contact details for study doctors 
Between 9am and 5 pm telephone 
029-20-744672
for emergencies outside these hours a study doctor can be contacted via the switchboard 
at Brighton hospital on:
012-73-696955
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Drugs which should not be used with sirolimus
Generic name Trade name(s)
Clarithromycin
Itraconazole
Ketoconazole
Rifabutin
Rifampicin
Telithromycin
Voriconazole
Klaricid, Klaracid XL
Sporanox
Nizoral
Mycobutin
Rifadin, Rimactane, Rifater, Rifinah 150, Rifinah 
300.
Rimactazid 150, Rimactazid 300
Ketek
Vfend
NB Grapefruit juice interacts with sirolimus and should be not drunk 
by someone taking sirolimus.
Drugs which should be avoided or used with caution in combination with sirolimus
Generic name Trade name(s)
Amiodarone
Barbiturates
Bromocriptine
Carbamazepine
Ciclosporin
Cimetidine
Ciprofloxacin
Clotrimazole
Danazol
Diltiazem
Erythromycin
Fluconazole
Fluvoxamine
CordaroneX
Amytal, Sodium Amytal, Soneryl, Seconal 
Sodium,
Tuinal
Parlodel
Tegretol, Tegretol Retard, Teril Retard Timonil 
retard 
Neoral, Sandimmun 
Dyspamet, Tagamet 
Ciproxin 
Canesten 
Danol
Tildiem, Adizem-SR, Adizem-XL. Angitil SR, 
Angitil
XL, Calciacard CR, Dilcardia SR, Dilzem SR, 
Dilzem
XL, Slozem, Tildiem LA, Tildiem Retard, Viazem 
XL,
Zemtard
Erymax, Erythrocin, Erythroped, Erythroped A
Diflucan
Faverin
Gestodene
Glucocorticoids (steroids) 
Prednisolone 
Betamethasone 
Cortisone 
Deflazacort
Femodette
not applicable 
Betnelan, Betnesol 
not applicable 
Calcort
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Dexamthasone 
Hydrocortisone 
Methylprednisolone 
Triamcinolone 
HIV antivirals
Atazanavir 
Amprenavir 
Efavirenz 
Indinavir 
Lopinavir 
Nelfinavir 
Nevirapine 
Ritonavir 
Saquinavir 
Ketoconazole 
Mifepristone 
Modafinil 
Nicardipine 
Norfloxacin 
Phenobarbital 
Phenytoin 
Pioglitazone 
St. John’s wort 
Verapamil
Decadron
Efcortesol, Hydrocortone, Solu-Cortef 
Medrone, Solu-Medrone, Depo-Medrone 
Kenalog
Reyataz
Agenerase
Sustiva
Crixivan
Kaletra
Viracept
Viramune
Norvir
Fortovase, Invirase 
Nizoral 
Mifegyne 
Provigil
Cardene, Cardene SR 
Utinor
not applicable
Epanutin
Actos
Cordilox, Securon, Half Securon SR, Securon SR, 
Univer, Verapress MR, Vertab SR 240.
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Appendix 4: Doctor’s information card
A study of the efficacy and safety of sirolimus (rapamycin) in 
tuberous sclerosis complex (TSC) and 
[ymphangioleiomyomatosis (LAM). (TESSTAL)
Dear (doctors name).
Re: (patient details)
Your patient (patient name) has agreed to participate in a study of the efficacy 
and safety of sirolimus therapy in patients with tuberous sclerosis and/ or 
lymphangioleiomyomatosis (LAM). (Sirolimus is known in the USA as 
rapamycin). Below is a summary of the study and information regarding 
sirolimus. Also attached is a copy of the patient information sheet.
The study
The primary aim of this study is to determine if sirolimus is effective in inducing 
regression of renal angiomyolipomas (AMLs) in persons with tuberous sclerosis 
complex (TSC), or sporadic lymphangioleiomyomatosis (LAM). A secondary 
aim is to determine whether sirolimus therapy affects respiratory function test 
results in LAM or the results of cognitive testing in TSC.
What patients are eligible for the study?
Patients with either tuberous sclerosis or sporadic lymphangioleiomyomatosis 
and one or more renal angiomyolipomas are potentially eligible.
What does the study involve?
After giving informed consent, patients will have a thorough baseline evaluation 
including a review of their medical history, physical examination, baseline blood 
tests, urine analysis, cognitive function tests, a chest X-ray and lung function 
tests. A high-resolution chest CT scan will also be performed in female patients 
where chest CT films from within the preceding twelve months are not available. 
All patients will have a baseline MRI of the brain and kidneys. Patients with TSC 
who have epilepsy will be given an epilepsy diary and instruction in its use. For 
participants with TSC whose genotype is not already known, blood will be 
drawn for genetic analysis.
As sirolimus is thought to be teratogenic women should not become pregnant 
whilst taking the drug nor should the partners of male participants. Female 
participants will have a pregnancy test on entry and at every study visit. 
Participants will be required to use an effective form of contraception during the 
study. Use of a contraceptive should continue for twelve weeks after stopping 
sirolimus.
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The patients will undergo regular follow up evaluations involving a combination 
of clinical review, blood tests, urine tests, lung function test and radiological 
examinations.
Unless they are withdrawn patients will be treated, as part of the study, for 2 
years.
What are the potential benefits?
This study may result in the identification of a medical treatment for renal 
angiomyolipomas in tuberous sclerosis. Untreated these lesions usually 
increase in size over time and lead to complications including haemorrhages 
and renal failure that are the second most common cause of death in TSC (after 
neurological causes). This may in turn lead to identification of sirolimus as an 
effective treatment for other progressive TSC lesions such as 
lymphangioleiomyomatosis or giant cell astrocytoma. This study may also result 
in a greater understanding of the development of hamartomatous malformations 
in TSC and other more malignant tumours in patients with TSC and the general 
population. This study may identify a useful treatment for sporadic LAM. This is 
a progressive condition and the only available treatments are supportive.
What are the potential risks?
Sirolimus is an immunosuppressant medication and has been associated with a 
number of potential risks. Sirolimus has been commercially available in the 
United States and UK since 1999. It is indicated for the prevention of renal 
transplant rejection in adult patients. As of July 2004, over 4000 patients have 
been treated with the drug. It has also been used to prevent rejection of other 
transplanted organs. In these patients, it is typically administered with other 
immunosuppressive agents such as tacrolimus, cyclosporin, or steroids. In 
addition to its immunosuppressive action, sirolimus may produce dose-related 
anaemia and thrombocytopenia, and a reversible idiosyncratic leucopoenia. 
Other individuals may experience dose related delay in wound healing and 
hyperlipidemia. This lipid alteration may require treatment with cholesterol 
lowering medications. An interstitial pneumonitis has been reported in 35 renal 
transplant patients receiving sirolimus (Wyeth database.) These individuals 
were also receiving immunosuppressants and lipid lowering drugs, and the 
interstitial pneumonitis resolved after withdrawal of sirolimus therapy. Other 
side effects seen are tachycardia, abdominal pain, diarrhoea, hypokalaemia, 
joint pain, acne and mouth ulcers. For the purposes of this protocol, sirolimus 
will be initiated at a dose lower than the recommended starting dose for 
immunosuppression, and will not exceed the recommended 
immunosuppressive starting dose. It is hoped that these measures will minimize 
the risk for side effects.
Since May 2003, patients with TSC have been treated with sirolimus in the USA 
in a parallel study. Side effects as of September 2004 have included oral
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ulceration in about one third of patients, and elevated serum lipids in about one 
quarter of patients. There have been a number of brief hospitalisations one for 
mouth ulcers causing inability to eat and drink, one for community acquired 
pneumonia which cleared while on sirolimus and two for diarrhoea attributed to 
Giardia, statins and possibly sirolimus. Although there have been several 
instances of bronchitis and upper respiratory infections, many of which 
prompted holding the drug, there have been no opportunistic infections or 
unexplained pulmonary infiltrates consistent with sirolimus pneumonitis.
Periodic laboratory tests will be performed to evaluate potential side effects of 
sirolimus. If patients develop significant side effects the dose of sirolimus may 
have to be reduced or the drug withheld. In the event of significant 
hyperlipidemia therapy with dietary modification and/or a HMG CoA reductase 
inhibitor (statin) +/- a fibrate will be initiated.
Sirolimus should be withheld for at least two weeks prior to and two weeks 
following elective surgery requiring more than three stitches, entry into a body 
cavity, or optimal healing (e.g.-laser dermatologic surgery on the face).
Sirolimus should be withheld for at least two weeks following accidents or 
emergency surgeries that meet the criteria above.
If you would like any advice about the management of medical problems in 
patients taking sirolimus or dose reduction in response to side effects then 
please contact a study doctor (contact details are at the end of this letter). 
Sirolimus may be discontinued at the discretion of any of the patient’s doctors.
Patients in this study will be exposed to a maximum of two high-resolution 
chest CT scans and one chest X-ray as part of the protocol.
An independent Trial safety monitoring committee will regularly review the 
study. They will be empowered to stop the study, at any time, (or withdraw an 
individual) if they perceive that the risks outweigh the potential benefits.
Drug i(iterations
Sirolimus is extensively metabolised by the CYP3A4 isoenzyme. Drugs which 
are inhibitors or inducers of this enzyme should be avoided if possible or used 
with caution (see table 1). Inhibitors of CYP3A4 may decrease the metabolism 
of sirolimus and increase sirolimus levels, while inducers of CYP3A4 may 
increase the metabolism of sirolimus and decrease sirolimus levels. Sirolimus 
may require dose adjustment or interruption during therapy with the following 
agents, and, conversely, dose adjustments or interruption of the following 
agents may be required during sirolimus therapy. Co-administration with strong 
inhibitors of CYP3 ( such as ketoconazole, voriconazole, itraconazole, 
telithromycin or clarithromycin) or strong inducers (such as rifampicin or 
rifabutin) is not recommended. Grapefruit juice is an inhibiter and should be 
avoided when taking sirolimus. If you would like any advice about the 
administration of any medication with sirolimus then please contact a study 
doctor (contact details are at the end of this letter).
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Tablel
Cytochrome P450 inhibitors and inducers
Inhibitors Inducers
Amiodarone
Bromocriptine
Cimetidine
Ciclosporin
(efavirenz,
Ciprofloxacin
Clarithromycin
Clotrimazole
Danazol
Diltiazem
Erythromycin
Fluconazole
Fluvoxamine St. John’s wort
Barbiturates 
Carbamazepine 
Glucocorticoids 
HIV antivirals
Phenobarbitone
Phenytoin
Pioglitazone
Rifabutin
Rifampicin
nevirapine)
Modafinil
Gestodene
HIV antivirals (atazanavir, amprenavir, indinavir, 
lopinavir, nelfinavir, ritonavir, saquinavir)
Itraconazole
Ketoconazole
Mifepristone
Nicardipine
Norfloxacin
Telithromycin
Verapamil
Voriconazole
Grapefruit juice interacts with sirolimus and should be avoided in someone 
taking sirolimus.
During treatment with sirolimus vaccination may be less effective. The use of 
live vaccines should be avoided during treatment with sirolimus.
183
Ethics.
We have obtained ethical approval for this study. The ethics approval is from 
the Thames Valley Multi-Centre Research Ethics Committee. Informed consent 
from all participants will be obtained prior to their entry into this study. All data 
will be kept strictly confidential and suitably anonymised prior to publication.
How we are asking you to help?
Patients will remain under the care of their principal physician but with regular 
review in the study centres. We would be grateful if any adverse effects were 
reported immediately to the study co-ordinator. We would also be grateful if you 
would inform any deputising services you use about this study.
If you have any specific concerns about your patient in relation to this study or 
any general enquiry about the study, please contact:
You can contact a study doctor between 9 am to 5 pm Monday to Friday on:
029-20-744672
For emergencies outside these hours you may contact the study doctor via the 
switchboard at Brighton hospital on:
01273-696955
Thank you.
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Appendix 5: Sample case report forms
N.B. Adverse event (1) was for local investigators, Adverse event (2) for 
the chief investigator or his delegate.
Adverse events (1)
Patient number:
Nature of event:
Date of event 
Start time
Stop time
Action taken re sirolimus
Treatment/ medication given 
(include date started and 
stopped/changed)
Event outcome
Seriousness non-serious serious
CTCAE description and grade (e.g. cardiac general, hypertension, grade 
2)
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Causality Not related
Unlikely
Possibly related 
Probably related 
Definitely related
expectedness expected
Time and date of notification of adverse event
Time and date study co-ordinator informed of adverse event
Name of P I__________________
Signed ___________________
unexpected
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Adverse event form II 
Patient number:
Nature of event:
Date of event 
Start time
Stop time
Seriousness non-serious
Causality Not related
Unlikely
Possibly related 
Probably related 
Definitely related
expectedness expected
serious
unexpected
CTCAE description and grade (e.g. cardiac general, hypertension, grade 
2)
Does this event need to be reported Yes
If yes
Time and date MHRA notified 
Time and date ethics committee notified 
Time and date Data and Safety committee notified
